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Abstract 
 
The role of  ped/pea-15 gene in the regulation of glucose homeostasis. 
The hyper-expression of Phosphoprotein Enriched in Diabetes/ Phosphoprotein 
Enriched in Astrocytes (Ped/Pea-15) gene is commonly found in human 
diabetic patients and causes impaired glucose tolerance in transgenic mice. 
Aim of this study was to investigate: i) PED/PEA-15 expression levels in first 
degree relatives (FDR) of patients with T2D and the possible correlation 
between PED/PEA-15 levels and diabetes subphenotypes; ii) the role of 
PED/PEA-15 in beta cell function in vivo. 
i) In Peripheral Blood Leucocytes (PBL) from the first degree relatives (FDR) 
of patients with T2D, PED/PEA-15 expression was two-fold higher than in 
euglycaemic individuals with no family history of diabetes (control subjects), 
both at the protein and the mRNA level (p<0.001). PED/PEA-15 expression 
was independent of sex and unrelated to age, Body Mass Index (BMI), waist 
circumference, systolic and diastolic Blood Pressure (BP), and fasting 
cholesterol, triacylglycerol and glucose levels. However, in euglycaemic FDR 
of T2 diabetic subjects, PED/PEA-15 expression was inversely correlated 
with insulin sensitivity (r=-557, p=0.01). ii) Transgenic mice with beta cell 
specific overexpression of ped/pea-15 (beta-tg) exhibited decreased glucose 
tolerance and impaired insulin response to hyperglycemia. Islets from the 
beta-tg also exhibited little response to glucose. Furthermore, overexpression 
of PED/PEA-15 reduce mRNAs encoding the Sur1 and Kir6.2 potassium 
channel subunits and their upstream regulator Foxa2, and inhibited the 
activity of the atypical PKCzeta by glucose both in mouse islets and in beta 
cells lines. Rescue of PKCzeta activity elicited recovery of the expression of 
the Sur1, Kir6.2 and Foxa2 genes and of glucose-induced insulin-secretion in 
PED/PEA-15 overexpressing beta cells. Interestingly, islets from ped/pea-15 
null mice exhibited a 2-fold increased activation of PKCzeta by glucose and 
abundance of the Sur1, Kir6.2 and Foxa2 mRNAs and enhanced glucose 
effect on insulin secretion. 
Thus, PED/PEA-15 overexpression represents a common defect in FDR and is 
correlated with reduced insulin sensitivity in these individuals, and its beta 
cell specific overexpression dysregulates beta cell function, restraining 
potassium channel expression in pancreatic beta cells and resulting in 
impaired glucose tolerance in vivo.  
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Background 
 
1 Glucose homeostasis 
   Despite periods of feeding and fasting, plasma glucose remains in a narrow 
range between 4 and 7 mM in normal individuals. This tight control is governed 
by the balance between glucose absorption from the intestine, production by the 
liver and uptake and metabolism by peripheral tissues (Saltiel and Kahn 2001). 
   Carbohydrate metabolism is regulated by several hormones, and also by 
sympathetic and parasympathetic nervous system activity (Table 1). The 
increasing glucose concentration after feeding (80/150 mg/dl) determines an 
increase of insulin release from pancreatic beta cells and a decrease of glucagon 
release from pancreatic alpha cells (Kahn 1994). Insulin lowers blood glucose 
levels both by suppressing glycogenolysis and gluconeogenesis in the liver  
(thereby decreasing hepatic glucose output), and by stimulating glucose uptake 
into skeletal muscle and adipose tissue. These actions are opposed by the 
“counter-regulatory” hormones, which are secreted continuously but whose 
release is enhanced during physiological “stress” (Pickup 2005). 
   Thus, the correct efficiency of pancreatic beta cells in insulin synthesis and 
secretion represents a fundamental role in glucose homeostasis maintenance.  
 
Table 1. Main hormones affecting carbohydrate metabolism 
 
HGO, hepatic glucose output. 
*Indirect enhancement of gluconeogenesis due to increased supply of glycerol and fatty acids by 
enhanced lipolysis 
§Increased gluconeogenesis by effects on hepatic enzymes and increased supply of glucogenic 
amino acids. 
 
2 Insulin  
   Insulin is the most potent anabolic hormone known. Secreted by pancreatic 
beta cells in response to increase of plasmatic glucose and amino acids levels 
after feeding, insulin promotes the synthesis and storage of carbohydrates, 
lipids and proteins, while inhibiting their degradation and release into the 
circulation. Insulin stimulates the uptake of glucose, amino acids and fatty 
acids into cells, and increases the expression and activity of enzymes that 
catalyse glycogen, lipid and protein synthesis, while inhibiting the activity or 
expression of those that catalyse degradation.  
   Insulin increases glucose uptake in muscle and fat, and it inhibits hepatic 
glucose production (glycogenolyisis and gluconeogenesis) in liver, thus serving 
as the primary regulator of blood glucose concentration. Insulin also stimulates 
cell growth and differentiation, and promotes the storage of substrates in fat, 
 Liver 
Gluconeogenesis
 
Glycogenolisys 
 
HGO 
Peripheral 
Glucose uptake 
Insulin ↓ ↓↓ ↓↓ ↑↑ 
Glucagon ↑↑§ ↑↑ ↑↑ - 
Catecholamines ↑↑*§ ↑ ↑↑ ↓ 
Growth hormone ↑* - ↑ ↓ 
Cortisol ↑*§ - ↑ ↓ 
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liver and muscle by stimulating lipogenesis, glycogen and protein synthesis, 
and inhibiting lipolysis, glycogenolysis and protein breakdown (Figure 1) 
(Saltiel and Kahn 2001). 
 
 
 
Figure 1 The regulation of metabolism by insulin. 
Insulin promotes the synthesis and storage of carbohydrates, lipids and proteins. Indeed, insulin 
stimulates the uptake of glucose, amino acids and fatty acids into cells, and increases the 
expression or activity of enzymes that catalyse glycogen, lipid and protein synthesis, while 
inhibiting the activity or expression of those that catalyse degradation. 
 
   Insulin is an hormone of 51 amino acids and is synthesized as a precursor 
protein (preproinsulin) in the beta cells. Preproinsulin presents a signal 
sequence at N-terminus that permits its entrance in secretion vesicles. The cut 
of the signal sequence by proteolytic enzymes produces proinsulin. When the 
increase of plasmatic glucose concentrations stimulates insulin secretion, 
proinsulin is converted in the mature hormone by specific proteases that 
hydrolyse two peptide bond and generate mature insulin (Taylor, et al. 1999).   
   Insulin is a little protein formed by two polypeptide chains, termed 
respectively “A” of 21 amino acids, and “B” of 30, linked by two interchain 
sulphide bond. 
   Once beta cells are stimulated by glucose, insulin is released in blood 
circulation and is distributed to target tissues, where it can bind a specific 
receptor at high affinity, essential for insulin signalling transduction.  
   
3 Insulin signaling system 
   Insulin action is mediated through the insulin receptor (IR), a transmembrane 
glycoprotein with intrinsic protein tyrosine kinase activity.  The insulin 
receptor belongs to a subfamily of receptor tyrosine kinases that includes the 
insulin-like growth factor (IGF)-I receptor and the insulin receptor-related 
receptor (IRR). These receptors are tetrameric proteins consisting of two α- 
and two β-subunits that function as allosteric enzymes where the α-subunit 
 9
inhibits the tyrosine kinase activity of the β-subunit. Insulin binding to the α-
subunit leads to derepression of the kinase activity of the β-subunit followed by 
transphosphorylation of the β-subunits and conformational change of the α 
subunits that further increases kinase activity (Patti and Kahn 1998).  
   Several intracellular substrates of the insulin receptor kinases have been 
identified (Figure 2). Four of these belong to the family of insulin-receptor 
substrate (IRS) proteins (White, et al. 1998). Other substrates include Gab-1 
and isoforms of Shc10 (Pessin and Saltiel 2000). The phosphorylated tyrosines 
in these substrates act as ‘docking sites’ for proteins that contain SH2 (Src-
homology-2) domains. Many of these SH2 proteins are adaptor molecules, 
such as the p85 regulatory subunit of PI(3)K and Grb2, or CrkII, which activate 
small G proteins by binding to nucleotide exchange factors. Others are 
themselves enzymes, including the phosphotyrosine phosphatase SHP2 and the 
cytoplasmic tyrosine kinase Fyn. 
   PI(3)K has a pivotal role in the metabolic and mitogenic actions of insulin 
(Shepherd, et al. 1995). It consists of a p110 catalytic subunit and a p85 
regulatory subunit that possesses two SH2 domains that interact with tyrosine-
phosphorylated motifs in IRS proteins (Myers MG Jr, et al. 1992). PI(3)K 
catalyses the phosphorylation of phosphoinositides on the 3-position to 
produce phosphatidylinositol-3-phosphates, especially PtdIns(3,4,5)P3, which 
bind to the pleckstrin homology (PH) domains of a variety of signalling 
molecules thereby altering their activity, and  subcellular localization (Lietzke, 
et al. 2000). Phosphotidylinositol-3-phosphates regulate three main classes of 
signalling molecules: the AGC family of serine/threonine protein kinases, the 
Rho family of GTPases, and the TEC family of tyrosine kinases. PI(3)K also 
might be involved in regulation of phospholipase D, leading to hydrolysis of 
phosphatidylcholine and increases in phosphatidic acid and diacylglycerol. The 
best characterized of the AGC kinases is phosphoinositide-dependent kinase 1 
(PDK1), one of the serine kinases that phosphorylates and activates the 
serine/threonine kinase Akt/PKB (Alessi, et al. 1997). Akt/PKB has a PH 
domain that also interacts directly with PtdIns(3,4,5)P3, promoting membrane 
targeting of the protein and catalytic activation. Akt/PKB has a pivotal role in 
the transmission of the insulin signal, by phosphorylating the enzyme GSK-3, 
the forkhead transcription factors and cAMP response element-binding protein. 
Other AGC kinases that are downstream of PI(3)K signaling include the 
atypical PKCs, such as PKC-ζ. Akt/PKB and/or the atypical PKCs are required 
for insulin stimulated glucose transport (Standaert, et al. 1997). 
   As is the case for other growth factors, insulin stimulates the mitogen-
activaed protein (MAP) kinase extracellular signal regulated kinase (ERK) 
(Figure 2). This pathway involves the tyrosine phosphorylation of IRS proteins 
and/or Shc, which in turn interact with the adapter protein Grb2, recruiting the 
Son-of-sevenless (SOS) exchange protein to the plasma membrane for 
activation of Ras. The activation of Ras also requires stimulation of the 
tyrosine phosphatase SHP2, through its interaction with receptor substrates 
such as Gab-1 or IRS1/2. Once activated, Ras operates as a molecular switch, 
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stimulating a serine kinase cascade through the stepwise activation of Raf, 
MEK and ERK. Activated ERK can translocate into the nucleus, where it 
catalyses the phosphorylation of transcription factors such as p62TCF, 
initiating a transcriptional programme that leads to cellular proliferation or 
differentiation (Boulton, et al. 1991).  
 
 
 
Figure 2 Signal transduction in insulin action. 
The insulin receptor is a tyrosine kinase that undergoes autophosphorylation, and catalyses the 
phosphorylation of cellular proteins such as members of the IRS family, Shc and Cbl. Upon 
tyrosine phosphorylation, these proteins interact with signaling molecules through their SH2 
domains, resulting in a diverse series of signaling pathways, including activation of PI(3)K and 
downstream PtdIns(3,4,5)P3-dependent protein kinases, ras and the MAP kinase cascade. 
These pathways act in a concerted fashion to coordinate the regulation of vesicle trafficking, 
protein synthesis, enzyme activation and inactivation, and gene expression, which results in the 
regulation of glucose, lipid and protein metabolism. 
 
4 Insulin secretion  
   Insulin concentration is normally determined by a feed-back control system 
that is responsive to the prevailing level of plasma glucose (Polonsky, et al. 
2001). The overall sensitivity of the pancreatic beta cell to glucose is 
determined by the sensitivity of peripheral tissues to the action of insulin with 
insulin-resistant subjects having higher insulin levels and insulin secretion rates 
than insulin sensitive subjects. Insulin is also secreted in response to amino 
acids and fatty acids and the magnitude of this response is modulated by a 
variety of neuronal (sympathetic and parasympathetic autonomic tone) and 
hormonal factors (glucagon, glp-1, and somatostatin). Glucose, however, is the 
overriding influence. Normal insulin secretion shows a rapid response to 
glucose and a complex profile. The increase in insulin secretion that occurs after 
the intravenous administration of glucose is virtually instantaneous; even after 
 11
oral glucose ingestion, increases in insulin secretion occur within minutes. The 
temporal profile of insulin secretion consists of small-amplitude pulses of 
insulin occurring every 5-10 minutes, superimposed on slower, larger-amplitude 
oscillations that occur every 1-2 hours.   
   After a glucose loading, it is possible to distinguish two insulin secretion 
phases. The first phase is characterized by a rapid increase of insulin release, 
immediately followed by a rapid fall of hormone plasmatic levels. The second 
phase, instead, is characterized by a prolonged insulin release up to 60 minutes 
after stimulation. At molecular level, the first phase requires  ATP and Ca++, and 
it reflects exocytosis profile of pool granules immediately disposable; second 
phase secretion also requires ATP and it results largely from exocytosis of 
insulin granules newly recruited to the plasma membrane (Mac Donald, et al. 
2005).  
   Pancreatic beta cells secretion can be roughly divided into two components: 
(i) the proximal events of glucose entry and metabolism and (ii) the distal 
mechanism of insulin secretion, spanning from mitochondrial signal generation 
and initiation of electrical activity to the ultimate effectors of insulin granule 
exocytosis.   
   Glucose is transported into beta cells by the glucose transporter 2 (GLUT2). 
Here, GK catalyses the transfer of phosphate groups from ATP to glucose to 
form glucose-6-phosphate, that enters glycolysis. ATP produced by glycolysis 
and the Krebs cycle is the conjunction ring between glucose catabolism and 
electric phenomena, that occur on plasma membrane and that are responsible, 
ultimately, for insulin release. ATP increase, indeed, leads to closure of the 
ATP-sensitive K+ (KATP) channel- a hetero-octamer formed by four subunits of 
the sulphonylurea 1 receptor (SUR1) and four subunits of the inwardly 
rectifying K+ channel Kir6.2, responsible for the regulation of the resting 
membrane potential. The closing of KATP channel leads to depolarization of the 
plasma membrane to a value of –40mV, and influx of extracellular calcium by 
the opening of type L voltage-dependent calcium channels (VDCC). Ca++  
entrance from extracellular space and the significant increase of its intracellular 
concentrations are considered the key events in the cascade events that leads to 
insulin secretion. Together with Ca++  mobilized from intracellular stores, this 
leads to fusion of insulin-containing secretory granules with the plasma 
membrane and the release of insulin into the circulation (Figure 3).   
   More than the increase of intracellular Ca++ concentrations, insulin secretion 
is sustained by the oscillation of Ca++ intracellular levels, paradigmatic of 
glucose metabolism oscillation. Three different types of Ca++ concentration 
oscillation can be observed during glucose stimulation: rapid and regular, slow 
and regular, or mixed, characterized by rapid oscillation superimposed to slow 
oscillation (Gilon, et al. 2002). According to recent hypothesis, metabolic 
oscillation depends on change of intracellular Ca++ concentration: Ca++ 
entrance determines an increase consumption of ATP and a reduction of its 
mitochondrial production. This, together with the direct inhibition of glycolysis 
by Ca++ , results in the decrease of ATP/ADP ratio, causing the reopening of 
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KATP channels. The consequent repolarization of beta cells determines the 
restore of Ca++ levels to basal values with the possibility that secretory process 
can be restarted (Kennedy, et al. 2002).  
 
 
 
Figure 3 The regulation of glucose induced insulin secretion. 
Glucose is transported into the beta cell by GLUT2, and is converted  in glucose-6-phosphate 
by GK. The generation of ATP by glycolysis and the Krebs cycle leads to closure of the ATP-
sensitive K+ channel. The closing of the KATP channel leads to depolarization of the plasma 
membrane and influx of extracellular calcium. Together with calcium mobilized from intracellular 
stores, this leads to fusion of insulin-containing secretory granules with the plasma membrane 
and the release of insulin into the circulation. 
 
4.1 Regulation of insulin secretion: glucose sensors 
   Glucose is required as an energy substrate, but it also functions as a signaling 
molecule in primary processes. Glucose sensors, molecular systems that 
accurately detect glucose concentrations in the extracellular space, contribute to 
maintain glucose homeostasis by controlling several key processes.  
   Beta cells of pancreatic islets act as glucose-sensors, adjusting insulin output 
depending on the prevailing blood glucose level (MacDonald, et al. 2005). It is 
possible in relation to existence of a beta cellular glucose-sensing mechanism 
able to measure extracellular glucose. The glucose sensor is constituted by the 
glucose transporter 2 (GLUT2) and glucokinase (GK). These proteins are both 
characterized by a low affinity to glucose and they are involved in high Km 
glucose transport and high Km phosphorylation of glucose, respectively, which 
allows increased glucose utilization as its concentration rises. Indeed, since 
GLUT2 and GK have a Km for glucose of 5 mmol/L, glucose uptake by 
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GLUT2 and glucose phosphorylation in glucose-6-phosfate by GK are rapid 
only after feeding, when glucose concentration are elevated, and this permits to 
glucose-sensing unit to be extremely sensitive to plasmatic glucose levels 
variation. Moreover, pancreatic beta cells appear to sense glucose 
concentrations through its catabolic products, such that the glucose catabolism 
rate must be proportional to glucose levels in the extracellular space (Mac 
Donald, et al. 2005). 
   However, glucose sensing does not directly depend on GLUT-2 activity. This 
glucose transporter plays a more permissive role in glucose catabolism, as 
glucose transport in beta cells is 100-fold higher than the rates of glucose 
metabolism. By contrast, GK catalyses the rate-limiting step of glucose 
catabolism, and controls glucose oxidation and adenosine triphosphate (ATP) 
formation, thus acting as a true glucose sensor (Mac Donald, et al. 2005). 
 
4.2 Regulation of insulin secretion: ATP-sensitive potassium channels 
   As early as 1970, ATP generation was implicated in the initiation of beta cell 
electrical activity based on the ability of 2,4-dinitrophenol (an uncoupler of 
oxidative phosphorylation) to prevent glucose-induced electrical responses in 
mouse islets. Subsequently, in mouse beta cells it was demonstrated the 
existence of K+ channels that were closed by glucose and ATP (Mac Donald, et 
al. 2005). 
   KATP channels are now known to be expressed in numerous tissues including 
smooth and skeletal muscle, neurons, peripheral axons and epithelial cells. The 
beta cell KATP channel was the first K+ channels cloned from insulinoma cells in 
1995, along with its regulatory sulphonylurea receptor (SUR) subunit (Aguilar-
Bryan, et al. 1995). There are currently two genes known for each of the KATP 
pore-forming subunits (Kir6.1 and 6.2) and the associated regulatory subunits 
(SUR1, 2), although diversity is further increased by alternative splicing of the 
SUR2 gene (Ashcroft and Gribble 1999). KATP channels are composed of four 
pore forming inward-rectifier potassium channel subunits (Kir6.2 in beta cells; 
two transmembrane domains) and four regulatory sulphonylurea receptor 
subunits (SUR1 in beta cells; total 17 transmembrane domains; Aguilar-Bryan 
and Bryan 1999).  
   In the absence of glucose KATP channels have a high open probability and 
mediate an outward K+ flux that holds the membrane potential near the 
equilibrium potential for K+ (approximately -70 mV). ATP can inhibit KATP 
channels at the Kir6.2 subunit in the absence of SUR1 and point mutations 
within Kir6.2 can attenuate the effect of ATP. A similar effect is mediated by 
the anti-diabetic sulphonylurea drugs through an interaction with SUR1, a 
member of the ATP-binding cassette super-family, stimulating insulin secretion 
even in the absence of glucose. The SUR1 subunit also binds ATP (both with 
and without Mg) and MgADP via the presence of two cytoplasmic nucleotide 
binding domains. Binding of MgADP to SUR1 is thought to stabilize the 
channel in the open configuration, and when the ATP-to-ADP ratio increases, 
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MgADP is displaced, and the Kir6.2 subunit becomes available for block by 
ATP (Mac Donald, et al. 2005). 
 
4.3 Regulation of insulin secretion: Protein Kinase C 
  The Protein Kinase C (PKC), identified for the first time as a 
Serine/Threonine kinase activated by Ca2+ and phospholipids, up to now can be 
divided in three subgroups based on cofactors requirements: classical PKCs (α, 
β, and γ), which are dependent on Ca2+ and diacylglycerol (DAG); novel PKCs 
(δ, ε, η and θ), activated by DAG; and atypical PKCs (ζ, λ, ι), which are not 
dependent on Ca2+ and DAG (Formisano, et al. 1998). 
   Several studies demonstrated that PKCs play an important role in controlling 
beta cell insulin secretion. These kinases, indeed, act in the beta cell amplifying 
the metabolic signals responsible for insulin release. In particular, PKC 
activation develops the insulin response to metabolic and not metabolic 
(sulphonylurea) stimuli, and it is necessary to observe the typical biphasic 
profile of insulin secretion. Eight isoforms of PKCs have been identified in the 
beta cells (α, γ, δ, ε, η, θ, ζ, λ), and two of these, PKCα and PKCε translocate 
to the membrane in response to glucose with different kinetics. PKCα migrates 
into the nucleus after two minutes from glucose stimulation, and subsequently 
localizes to the plasma membrane. The block of PKCα translocation 
determines a 40% decrease of glucose induced insulin secretion. This depends 
on the role of PKCα in phosphorilating and, thus, activating several 
components of SNARE complex involved in the exocytosis process (Nesher, et 
al. 2002). Instead, PKCε colocalizes, in response to glucose, with insulin 
containing granules, but its translocation to the plasma membrane is slower (15 
minutes) compared to PKCα. Probably PKCε  is involved in the pro-insulin 
processing and in the mobilization of granules. Moreover, in vitro studies have 
demonstrated that PKCε is necessary for glucose and sulphonylurea induced 
insulin secretion since the expression of a negative double mutant of the 
protein abolished completely insulin secretion. On the other hand, the 
overexpression of the kinase determined a significant increase of insulin 
secretion (Mendez, et al. 2005). 
   Atypical PKCs have been reported to control also the function of a number of 
transcription factors. PKCλ has recently been shown to play a major role in 
regulating glucose-induced insulin secretion by modulating the expression of 
genes involved in this process (Hashimoto, et al. 2005). Indeed, islets from mice 
that lack PKCλ in pancreatic beta cells show impaired insulin secretion in 
response to hyperglycaemia whereas the basal rate of insulin release is 
increased. This depends on the ability of PKCλ to regulate glucose-induced 
insulin release by modulating the transcriptional expression of genes important 
for beta cell function such as Glut-2, Foxa2, Sur1, Kir6.2, and hexokinase 1 and 
2. 
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5 Diseases with insulin secretion deficiencies 
  Maturity-onset diabetes of the young (MODY), Persistent Hyperinsulinemic 
Hypoglycemia of Infancy (PHHI), mitochondrial diabetes, Type 1 (T1D) and 
Type 2 Diabetes (T2D) are a heterogeneous group of disorders characterized by 
insulin secretory abnormalities and by high blood glucose levels.  
   In subjects with MODY, PHHI, or mitochondrial diabetes, the elevation in 
blood glucose levels is due to genetically determined defects in processes that 
are critical for the normal signaling pathways in the beta cell. The effects of 
these mutations on insulin secretion are so severe that diabetes develops in 
people with normal or relatively normal insulin sensitivity and without the 
contribution of environmental factors. In T1D, instead, insulin secretory 
abnormalities results from an absolute deficiency of insulin due to 
autoimmunological destruction of the insulin-producing pancreatic beta cell. 
Finally, in T2D, more moderate abnormalities of secretion are present that cause 
glucose intolerance only if insulin resistance is also present. The genetic basis of 
beta cell dysfunction in this form of diabetes is more complex, involving both 
multiple interacting genes and environmental factors, which determine whether 
diabetes will develop and at what age. Here no genetic abnormalities profoundly 
affect beta-cell function, but rather the inability of the pancreatic beta cell to 
adapt to the reductions in insulin sensitivity that occur over a lifetime 
precipitates the onset of hyperglycaemia (Bell and Polonsky 2001). 
 
5.1 MODY, PHHI, and mitochondrial diabetes 
   MODY is a clinically heterogeneous group of disorders characterized by non-
ketotic diabetes mellitus, an autosomal dominant mode of inheritance, onset 
usually before 25 years of age and frequently in childhood or adolescence, and a 
primary defect in pancreatic beta cell function. MODY can result from 
mutations in any one of at least six different genes that encode the glycolytic 
enzyme glucokinase and five transcription factors: hepatocyte nuclear factor 
(HNF)-4α, HNF-1α, insulin promoter factor-1 (IPF-1), HNF-1β and neurogenic 
differentiation 1/beta cell E-box transactivator 2 (NeuroD1/BETA2) (Table 2). 
All the mentionated genes are expressed in the pancreatic beta-cell and 
mutations lead to beta cell dysfunction and diabetes mellitus in the heterozygous 
state (Bell and Polonsky 2001).  
 
Table 2 MODY classification and genes 
 
MODY Gene involved 
MODY 1 HNF-4α 
MODY 2 GK 
MODY 3 HNF-1 α 
MODY 4 IPF-1 
MODY 5 NEURO D1/BETA 2 
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   GK is expressed at highest levels in the pancreatic beta cell and in the liver. It 
catalyses the transfer of phosphate groups from ATP to glucose to generate 
glucose-6-phosphate: the first rate-limiting step in glucose metabolism. GK 
functions as the glucose sensor in the beta cell and influences the ability to store 
glucose as glycogen in the liver. Heterozygous mutations leading to partial 
deficiency of GK are associated with MODY and homozygous mutations 
usually result in complete deficiency of this enzyme, leading to PHHI (Bell and 
Polonsky 2001)..  
   The transcription factors HNF-1α, HNF-1β and HNF-4α are involved in the 
tissue-specific regulation of gene expression in the liver, pancreatic beta cells 
and other tissues. HNF-1α and HNF-1β are members of the homeodomain-
containing family of transcription factors and HNF-4α is an orphan nuclear 
receptor. They are part of a network of transcription factors that controls gene 
expression during embryonic development and also in adult tissues where they 
are co-expressed. In the pancreatic beta cell, they regulate the expression of 
genes important in the regulation of insulin secretion. Mutations in these genes 
produce defects in insulin secretory responses to a variety of factors, 
particularly glucose, which are present before the onset of hyperglycaemia. In 
mice lacking the gene for HNF-1α, beta cell mass fails to increase despite the 
presence of hyperglycaemia, suggesting that this transcription factor may 
regulate beta cell mass (Bell and Polonsky 2001). 
IPF-1 is a homeodomain-containing transcription factor involved in 
pancreatic development, transcriptional regulation of a number of beta cell 
genes including insulin, glucokinase, islet amyloid polypeptide and GLUT2, 
and mediation of glucose-stimulated insulin gene transcription. Mutations in the 
heterozygous state are associated with MODY, whereas mouse and human 
homozygotes fail to develop a pancreas and suffer congenital diabetes mellitus. 
IPF-1 mutations have also been discovered in a small fraction of patients with 
typical adult-onset type 2 diabetes. Subjects with heterozygous mutations in 
IPF-1 demonstrated reduced insulin secretory responses to glucose and 
glucagon-like peptide-1, consistent with a defect in the signalling pathways that 
regulate secretion in the beta cell and/or a defect in beta cell mass. 
The basic helix–loop–helix transcription factor NeuroD1/BETA2 is involved 
in the regulation of transcription of the insulin gene and is required for normal 
pancreatic islet development. Mutations in NeuroD1 are a rare cause of MODY 
and result in reduced serum insulin concentrations, either due to a signalling 
defect in the beta cell, or a reduction in beta cell mass, or both (Bell and 
Polonsky 2001). 
   PHHI, also known asfamilial hyperinsulinism, pancreatic nesidioblastosis or 
hyperinsulinemic hypoglycemia, is a rare genetic disease, that can be inherited 
in a dominant or recessive way. It is mainly characterized by the presence of 
inappropriately high levels of insulin in parallel with low or very low 
glucose levels. This disease affects newborns and infants and it is as frequent as 
1:50000 for unselected populations. Mutations in four different genes have been 
identified: the KATP channel genes SUR1 and Kir6.2, glucokinase (GK), and 
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glutamate dehydrogenase (GLUD1). Nevertheless, in as many as 60% of 
patients, the genetic basis of the condition has not been elucidated. The most 
common and most severe forms of PHHI arise from SUR1 (40 different 
mutations) and/or Kir6.2 (three mutations) gene defects and alterations of beta 
cellular KATP channels are responsible for PHHI physiopathology. Using both 
recombinant expression systems and beta cells isolated from patients after 
surgery, investigators have shown these mutations to lead to impaired 
trafficking or assembly of KATP channels or to cause defects in the ADP-
dependent regulation of channel activity, and it results in depolarized beta cells 
with unregulated Ca2+ channel activity, that determines hypoglycaemia and 
impaired insulin secretion (Kane, et al. 1996; Straub, et al. 2001). 
   In addition to mutations in the nuclear genome, abnormal mitochondrial 
function resulting from mutations in the mitochondrial genome can lead to 
diabetes. The most common diabetes-associated mutation is an A-to-G 
transition in the mito-chondrial tRNALeu(UUR) gene at base pair 3,243. This 
mutation results in defects in insulin secretion including failure of glucose to 
prime the insulin secretory response and abnormal insulin secretory oscillation 
(Bell and Polonsky 2001). 
 
5.2 Type 1 diabetes  
   T1D accounts for 10% of all diabetes cases. The disease can affect people of 
any age, but usually occurs in children or young adults. T1D is caused by an 
auto-immune reaction againist the insulin-producing cells. The reason why this 
occurs is not fully understood. T1D pathogenesis involves environmental 
triggers that may activate autoimmune mechanisms in genetically susceptible 
individuals. It is characterized by insulitis, an infiltration of the pancreatic 
islets by lynphocytes, macrophages and neutrophil granulocytes, resulting in 
auto-immune destruction of the beta cells since chronic exposure to pro-
inflammatory cytokines such as IL-1, TNFα, and interferon γ is cytotoxic to 
beta cells. The clinical manifestation of T1D is typically late-stage, when 
majority of beta cells (90%) have been destroyed and its onset is often sudden 
and dramatic. The lives of people with this form of diabetes are entirely 
dependent on injections of insulin every day for survival in order to prevent the 
development of ketoacidosis. (Diabetes Atlas 2006) 
 
5.3 Type 2 diabetes  
   T2D is the most common type of diabetes and accounts for 90% of all forms 
of diabetes. T2D is most common in people older than 45 who are overweight. 
However, as a consequence of increased obesity among young people, it is 
becoming more common in children and young adults.  
   T2D is a heterogeneous syndrome with many possible causes. This is due to 
the interaction of environmental factors with a genetic susceptibility to the 
disease (Table 3), and it is becoming more and more evident that the relative 
contribution of genes and environment can differ considerably, even among 
individual whose clinical phenotype is similar (Diabetes Atlas 2006). 
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   The maintenance of normal glucose homeostasis depends on a precisely 
balanced and dynamic interaction between tissue sensitivity to insulin and 
insulin secretion. Type 2 diabetes develops because of defects in both insulin 
secretion and action, both of these with a genetic as well as an acquired 
component. Thus, T2D is made up of different forms each of which is 
characterized by variable degrees of insulin resistance and beta cell 
dysfunction, and which together  lead to hyperglycaemia. 
   Insulin resistance, typically, is an early feature of T2D. It results from a 
genetically determined reduction in insulin sensitivity, compounded by 
exposure to the environmental factors, which further impair insulin action. 
Major sites of insulin resistance include liver and the peripheral tissues, 
skeletal muscle and fat. In muscle and fat, insulin resistance is manifested by 
decreased glucose uptake; in muscle, it impaired utilization of glucose by non-
oxidative pathways as well as by decrease in glucose oxidation; in the liver, 
insulin resistance leads to failure of insulin to suppress hepatic glucose 
production, which is fulled by glycogen breakdown and particularly by 
gluconeogenesis (Pickup 2005) (Figure 4). 
 
 
 
 
Figure 4. Insulin resistance on tissue targets. 
The main sites of insulin resistance are liver and the peripheral tissue, skeletal muscle and fat. 
insulin resistance is manifested by decreased glucose uptake in muscle and fat, and by failure 
of insulin to suppress hepatic glucose production in the liver. 
 
The beta cell dysfunction ,the other key component of T2D pathophysiology, 
involves a relatively selective defect in the ability of glucose to provoke insulin 
secretion by beta cells, a temporal irregularity in the pulse and oscillations of 
insulin secretion, and a loss of the tight coupling between pulses of insulin 
secretion and pulse in glucose. This defect accounts for the failure of  beta cells 
to compensate for increasing insulin-resistance and for the ultimate 
development of overt hyperglycaemia.  
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   The disease often remains asymptomatic and undetected for years. People 
with T2D do not usually require injections of insulin, and they control their 
blood glucose levels by watching their diet, taking regular exercise, oral 
medication, and possibly insulin. But if T2 diabetic people are not diagnosed 
and treated, they can develop serious complications, which can result in early 
death. Indeed, as glycaemic control deteriorates over time, patients are at 
increased risk of microvascular complications (disease of the small blood 
vessels) including retinopathy, neuropathy and nephropathy, and macrovascular 
complications (disease of the large blood vessels) including coronary heart 
disease, myocardial infarction and stroke. As a result, diabetes affects almost 
every element of the human body, as can be seen in figure 5. 
 
 
 
Figure 5. The major diabetic complications. 
Diabetic patients are at increased risk of microvascular complications (disease of the small blood 
vessels) including retinopathy, neuropathy and nephropathy, and macrovascular complications 
(disease of the large blood vessels) including coronary heart disease, myocardial infarction and 
stroke. 
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Table 4. T2D risk factors 
 
 
5.4 Genes in type 2 diabetes 
   As mentioned above, insulin resistance and impaired beta cell function are 
the prominent features of T2D, and it is contributed by genetic and 
environmental factors. These factors might affect either the process of insulin 
signal transmission across the plasma membrane and/or the biochemical 
pathways allowing glucose uptake and metabolism by the cells, or might affect 
the pathways regulating beta cell function, including those for beta cell 
compensation. While several environmental factors have been identified, 
discovery and characterization of the genes involved in T2D has been an 
arduous task and has proceeded slowly. In the past 10 years, indeed, geneticists 
have devoted a large amount of effort to finding T2D genes. These efforts have 
included many candidate-gene studies, extensive efforts to fine map linkage 
signals, and an international linkage consortium that was perhaps the best 
example of a multi-centre collaboration in common-disease genetics (Genome 
Wide Association Studies, GWAS). Of these efforts, only the candidate-gene 
studies produced unequivocal evidence for common variants involved in T2D. 
These are the E23K variant in the potassium inwardly-rectifying channel, 
subfamily J, member 11 (KCNJ11) gene (Nielsen, et al. 2003), the P12A 
variant in the peroxisome proliferator-activated receptor-γ (PPARG) gene 
(Altshuler, et al. 2000), and common variation in the transcription factor 2, 
hepatic (TCF2) (Gudmundsson, et al. 2007) and the Wolfram syndrome 1 
(WFS1)10 genes (Sandhu, et al. 2007). All of these genes encode proteins that 
have strong biological links to diabetes. Rare, severe mutations in these four 
genes cause monogenic forms of diabetes, and two of them are targets of anti-
diabetic therapies: KCNJ11 encodes a component of a potassium channel with 
a key role in beta cell physiology and it is targeted by the sulphonylurea class 
of drugs; PPARG encodes a transcription factor involved in adipocyte 
differentiation and it is targeted by the thiazolodinedione class of drugs (Figure 
6). 
Major risk factor 
Demographic factors 
- Race and ethnic background (native American, Polynesian islanders, African-American)
- Age ≥ 45 years 
Family history: first-degree relatives with type 2 diabetes 
Obesity: BMI ≥ 27 Kg/m2 with central fat distribution 
History of impaired fasting glucose or impaired glucose tolerance 
Hypertension (blood pressure ≥ 140/90 mmHg) 
HDL cholesterol level ≤ 0.90 mmol/l and/or a triglyceride level ≥2.8 mmol/l 
Other risk factors 
Malnutrition in the first year of life, and particularly in utero 
Lifestyle factors 
- Physical inactivity 
- High-fat, low-carbohydrate diet 
- Alcohol (heavy consumpition) 
- Smoking 
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   A common amino-acid polymorphism (Pro12Ala) in peroxisome proliferator-
activated receptor-γ (PPARγ) has been associated with T2D. People 
homozygous for the Pro12 allele are more insulin resistant than those having 
one Ala12 allele and have a 1.25-fold increased risk of developing diabetes. 
Moreover, there is also evidence for interaction between this polymorphism 
and fatty acids, thereby linking this locus with diet (Altshuler, et al. 2000). 
   In 2006, by far the most spectacular recent development in the field of 
multifactorial T2D genetics has been the identification of TCF7L2 (encoding 
transcription factor 7-like 2) as the most important T2D-susceptibility gene to 
date (Owen, et al. 2007). The estimate of effect size (an odds ratio for T2D of 
1.4-fold per allele) was identified in an intronic SNP with uncertain functional 
credentials (rs7903146). TCF7L2 variation is strongly associated with rates of 
progression from impaired glucose tolerance to diabetes (with a hazard ratio of 
1.55 between homozygote groups). TCF7L2 is widely expressed and involved 
in the Wnt signalling cascade. Most studies suggest that the predominant 
intermediate phenotype associated with TCF7L2 variation is impaired insulin 
secretion, consistent with the replicated observation that the TCF7L2 
association is greater among lean than obese T2D subjects. Early mechanistic 
hypotheses have focused on the known role of TCF7L2 in the gut, postulating 
the involvement of impaired release of glucagon-like peptide-1 (an important 
islet secretagogue), reduced beta cell mass or intrinsic beta cell dysfunction. 
Body mass index data and some preliminary associations with leptin and 
ghrelin levels, however, could point towards a central mechanism.  
   TCF7L2 result was encouraging for two reasons. First, this study analysed 
more than 200 markers across a region of linkage on chromosome 10q, but the 
variants that were found to alter risk did not explain the linkage signal, 
suggesting that a non-candidate-gene or region-based association effort (such 
as a GWAS) could work. Second, TCF7L2 was a completely unexpected gene-
this showed that a genome-wide approach could uncover previously 
unexpected disease pathways.    
 
6 PED/PEA-15 identification 
   In our laboratory, to identify genes whose expression is altered in T2D, we 
have used a differential display approach (Condorelli, et al. 1998). We analysed 
pools of mRNA extracted from fibroblasts derived from six T2 diabetics and six 
non-diabetic individuals. We obtained forty-five bands appeared to be 
differentially expressed in the two groups of fibroblasts. Out of these, eight 
bands were confirmed to be overexpressed and 12 were expressed at lower 
levels in T2 diabetic fibroblasts compared with those from the non-diabetic 
individuals. The clones, termed 10.1, was selected, and the expression profile 
analyzed by dot-blot analysis. The 10.1 probe hybridized 2-fold more intensely 
to RNA preparations from fibroblasts, skeletal muscle and adipose tissues in the 
T2 diabetics compared with the non-diabetics. Northern blot analysis are 
fibroblasts RNA showed that the 10.1 probe hybridized to a major 2.8 kb band. 
To obtain the full-length cDNA, we have screened a human heart library with 
 22
the 10.1 clone. One of nine positive clones isolated corresponds to the protein 
kinase C (PKC) substrate PEA-15 (phosphoprotein enriched in astrocytes) 
(Condorelli, et al. 1998).  
 
 
Figure 6. Effect sizes of the 11 common variants confirmed to be involved in 
type 2 diabetes risk. 
The x axis shows the year when published evidences reached the levels of statistical 
confidence that are now accepted as necessary for genetic association studies. CDKAL1, CDK5 
regulatory subunitassociated protein 1-like 1; CDKN2, cyclin-dependent kinase inhibitor 2A; 
FTO, fat mass and obesity-associated; HHEX, haematopoietically expressed homeobox; IDE, 
insulin-degrading enzyme; IGF2BP2, insulin-like growth factor 2 mRNA-binding protein 2; 
KCNJ11, potassium inwardly-rectifying channel, subfamily J, member 11; PPARG, peroxisome 
proliferator-activated receptor-γ gene; SLC30A8, solute carrier family 30 (zinc transporter), 
member 8; TCF2, transcription factor 2, hepatic; TCF7L2, transcription factor 7-like 2 (T-cell 
specific, HMg-box); WFS1, Wolfram syndrome 1. 
 
 
7 PED/PEA-15 
   Phosphoprotein enriched in diabetes/phosphoprotein enriched in astrocytes 
(PED/PEA-15) was originally identified as a major astrocytes phosphoprotein 
and it was found to be widely expressed in different tissue and highly 
conserved among mammals. PED/PEA-15 is a 15 kDa cytosolic protein whose 
gene maps on human chromosome 1q21-22 (Condorelli, et al. 1998). It is a 
highly regulated protein with two major phosphorylation sites on Ser104 and 
Ser116. Indeed, PED/PEA-15 is phosphorylated at Ser104 by protein kinase C 
(PKC) and at Ser116 by calcium-calmodulin kinase II (CaMKII) and by 
Akt/PKB (Kubes, et al. 1998; Trencia, et al. 2003). Thus, PED/PEA-15 is 
present in the cell in the unphosphorylated (N), singly phosphorylated (Pa), and 
doubly phosphorylated (Pb) form. Moreover, it presents at N-terminus the 
protein-protein interaction domain DED (Death Effector Domain) and a 
Nuclear Export Sequence (NES), that localizes the protein prevalently in the 
cytosol. 
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Figure 7. PED/PEA-15 structure. 
PED/PEA-15 protein presents at N-terminus the protein-protein interaction domain DED (Death  
Effector  Domain) and a Nuclear Export Sequence (NES), that localizes the protein prevalently 
in the cytosol. The two major phosphorylation sites on Ser104 and Ser116. are visualized. 
 
   Several studies in cultured cells and in rodent tissues have revealed that 
PED/PEA-15 is a multifunctional protein. i) it regulates multiple cellular 
functions by binding to distinct components of major intracellular transduction 
pathways (Formstecher, et al. 2001; Vaidyanathan and Ramos 2003). These 
include ERK1/2, Akt/PKB, and RSK2. ii) it has been shown to exert 
antiapoptotic action through distinct mechanisms. First, PED/PEA-15 inhibits 
the formation of the death-inducing signaling complex (DISC) and caspase 3 
activation by different apoptotic cytokines including FASL, tumor necrosis 
factor alpha, and tumor necrosis factor-related apoptosis-inducing ligand 
(TRAIL) (Condorelli, et al. 1999, Hao, et al 2001). At least in part, this action 
is accomplished through the death-effector-domain of PED/PEA-15 upon 
PED/PEA-15 recruitment to the DISC. Secondly, PED/PEA-15 inhibits the 
induction of different stress-activated protein kinases (SAPKs) triggered by 
growth factor deprivation, hydrogen peroxide, and anisomycin (Condorelli, et 
al. 2002). This action of PED/PEA-15 is exerted by the blocking of an 
upstream event in the SAPK activation cascade and requires the interaction of 
PED/PEA-15 with ERK1/2. Thirdly, PED/PEA-15 modulates apoptosis upon 
UVC exposure in a dose-dependent fashion. Indeed, at least in part, apoptosis 
following Omi/HtrA2 mitochondrial release is mediated by reduction in PED-
PEA15 cellular levels (Trencia, et al. 2004). Thus, the ability of Omi/HtrA2 to 
relieve XIAP inhibition on caspases is modulated by the relative levels of 
Omi/HtrA2 and PED/PEA-15. iii) it plays an important role in tumor 
development and sensitivity to antineoplastic agents (Formisano, et al. 2005).    
   Indeed, the expression levels of PED/PEA-15 control Caspase-3 function and 
epidermal cell apoptosis in vivo and determine susceptibility to skin tumor 
development. iiii) PED/PEA-15 also binds to and increases the stability of 
phospholipase D, enhancing its activity and controlling important mechanisms 
in cell metabolism (Zhang, et al. 2000). In cultured muscle and adipose cells 
and in peripheral tissues from transgenic mice, high levels of PED/PEA-15 
impair insulin-stimulated GLUT4 translocation and glucose transport, 
suggesting that PED/PEA-15 overexpression may contribute to insulin 
resistance in Type 2 diabetes (Condorelli, et al. 2001; Vigliotta, et al. 2004). 
PKC
AKT/CaMK2
81 130
C-terminusDED
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S104
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Moreover, other studies have demonstrated that PED/PEA-15-induced 
resistance to insulin action on glucose disposal is accompanied by PLD-
dependent activation of the classical protein kinase C isoform PKCalpha. In 
turn, the induction of PKCalpha by PED/PEA-15 prevents subsequent 
activation of the atypical PKCzeta by insulin. Rescue of PKCzeta activity in 
cells overexpressing PED/PEA-15 restores normal sensitivity to insulin of the 
glucose transport machinery (Condorelli, et al. 2001). Thus, in muscle and 
adipose cells, PED/PEA-15 generates resistance to insulin action on glucose 
disposal by impairing normal regulation of PKCzeta. Transgenic mice 
ubiquitously overexpressing ped/pea-15 (Tg-PED) to levels similar to those 
found in many type 2 diabetics exhibited mildly elevated random-fed blood 
glucose levels and decreased glucose tolerance. Treatment with a 60% fat diet 
led ped/pea-15 transgenic mice to develop diabetes. Consistent with insulin 
resistance in these mice, insulin administration reduced glucose levels by only 
35% after 45 min, compared to 70% in control mice, and insulin-stimulated 
glucose uptake was decreased by almost 50% in fat and muscle tissues. In 
addition to insulin resistance, ped/pea-15 transgenic mice showed a 70% 
reduction in insulin response to glucose loading (Figure 8). Thus, in vivo, 
overexpression of ped/pea-15,in addition to generating insulin resistance and 
altered glucose tolerance, may impair beta-cell function and glucose-induced 
insulin secretion (Vigliotta, et al. 2004).  
 
 
Figure 8. Tg-PED metabolic phenotype. 
a) Glucose Tolerance Test, b) Insulin Tolerance Test and c) glucose-induced insulin secretion 
were performed in Tg-PED and in their control mice (C). 
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Aims of the study 
 
   This thesis concerns the study of the role of ped/pea-15 gene in the 
regulation of glucose homeostasis.  
   The hyper-expression of Phosphoprotein Enriched in Diabetes/ 
Phosphoprotein Enriched in Astrocytes gene is commonly found in human 
diabetic patients. Earlier findings in humans, indeed, evidenced that the 
PED/PEA15 gene is overexpressed in skeletal muscle and fat tissues as well as 
in cultured skin fibroblasts from individuals with type 2 diabetes, and this 
effect occurs independently of obesity, suggesting that it may be a primary 
component of insulin resistance in these subjects. Moreover, PED/PEA-15 
overexpression causes insulin-resistance and impaired glucose tolerance in 
transgenic mice (TgPED). In these mice, PED/PEA-15 overexpression 
determines also an increase of insulin fasting levels. Furthermore, insulin levels 
do not change after glucose injection, suggesting a defect on insulin secretion 
regulation. However, the physiologic function of PED/PEA-15 and the 
mechanism through which PED/PEA-15 overexpression can impair glucose 
tolerance are not clear.  
   In this context, I have investigated: i) whether PEA15 overexpression occurs 
in individuals at high risk of diabetes and whether it is associated with specific 
type 2 diabetes subphenotypes, ii) the role of PED/PEA-15 in beta-cell 
function.  
   For the first point, I analysed PED/PEA15 expression in euglycaemic first-
degree relatives (FDR) of type 2 diabetic subjects, and evaluated the possible 
correlation between PED/PEA-15 levels and diabetes subphenotypes 
For the second point, I generated and characterized a transgenic mice featuring 
selective overexpression of PED/PEA-15 in the beta-cells (beta-Tg), and I tried 
to identify the molecular mechanism through which PED/PEA-15 induces 
beta-cell dysfunction on pancreatic islets isolated from beta-Tg mice and on a 
beta cell cellular model stably overexpressing PED/PEA-15 cDNA. 
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Materials and Methods 
 
Subjects  
   The subjects investigated in the present study were recruited at the outpatient 
facilities of the Metabolic Unit at the University of Catanzaro ‘Magna Graecia’ 
(offspring from the European Network on Functional Genomics of Type 2 
Diabetes [EUGENE2] study). Written informed consent was obtained from all 
participants. The study protocol was approved by the ethics committee of the 
institution and conducted in accordance to the principles of the Declaration of 
Helsinki as revised in 2000. The euglycaemic individuals were healthy 
employees of the Campania Region. The presence of type 2 diabetes affected 
first-degree relatives (FDR) was ascertained through a written questionnaire 
and further verified through the medical history. The average number of 
relatives with type 2 diabetes in the subgroup of FDR was 1.1. Anthropometric 
indexes (BMI was calculated by dividing the weight in kilograms by the square 
of the height in metres; waist circumference was measured midway between 
the lowest rib margin and the iliac crest to the nearest 0.5 cm) and detailed 
medical history were obtained from all of the participants. Blood pressure, 
plasma glucose, total cholesterol, HDL cholesterol, and serum insulin levels 
were determined. The OGTT and euglycaemic–hyperinsulinaemic clamp 
procedures were performed. Briefly, for clamp studies, insulin (Humulin; Eli 
Lilly, IN) was given as a prime contiuous infusion to produce plasma insulin 
levels of 420 pmol/l. Thereafter, the insulin infusion rate was fixed at 40 mU 
m-2 min-1. Blood glucose was maintained at a constant level throughout the 
study by infusing 20% glucose at varying rates according to blood glucose 
measurements performed at 5-min intervals. Lean body mass was assessed by 
bioimpedence. Duration of the clamp was 120 min. Glucose disposal is 
expressed as milligrams per kilogram of lean body per mass per minute. Insulin 
secretion was estimated by the homeostasis model assessment of pancreatic 
beta cell function (HOMA-B) index and the insulinogenic index as the 
difference between the 30- and 0-min OGTT plasma insulin values divided by 
the difference between the corresponding plasma glucose values, (∆I30/∆G30). 
 
Separation of white blood cells  
   For peripheral blood leucocyte (PBL) separation, EDTA-treated whole-blood 
samples were first centrifuged at 300 ×g for 10 min and the plasma removed. 
PBLs were separated using a 6% dextran gradient in filtered PBS, pH 7.4, 
washed in PBS three times, counted and resuspended in 1 ml of PBS for 
subsequent use. Neutrophils and other major leucocyte subpopulations were 
further separated, as described (Metcalfe and Waters 1992). The purity of the 
different cell populations was confirmed by microscopic examination.  
 
Generation of transgenic mice 
   The rip-I/ped/pea-15 chimeric gene was obtained by introducing a 2.3-Kb 
EcoRI fragment containing the entire human ped/pea-15 cDNA at the EcoRI 
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site in a pB5-RIP-β-globin expression vector (kindly provided by Prof. D. 
Accili, Columbia University, N.Y.). This chimeric gene was microinjected into 
fertilized C57BL6/SJL mouse eggs. The general procedures used for 
microinjection and animal selection have been previously described 
(Devedjian, et al. 2000). Six F0 founders were identified by PCR as in 
(Vigliotta, et al. 2004). Mice were fed ad libitum with a standard diet (Research 
Diets formulas D12328; Research Diets, Inc., N.J.) and kept under a 12 hour-
light/12 hour-dark cycle. All procedures described below were approved by the 
Institutional Animal Care and Utilization Committee.  
 
Determination of glucose and insulin tolerance, assessment of insulin 
secretion and of glucose utilization.  
   Glucose tolerance tests, insulin tolerance tests and insulin secretion were 
measured as previously described (Kulkarni, et al. 1999; Bruning, et al. 1998). 
For analysing glucose utilization by skeletal muscle, an intravenous injection 
of 1 µCi of the nonmetabolizable glucose analog 2-[1-3H]deoxy-D-glucose (2-
DG) (Amersham Pharmacia Biotech, NJ) and an intraperitoneal injection of 
insulin (0.75 mU/g of body weight) were administered to random fed mice. 
The specific blood 2-DG clearance was determined with 25µl blood samples 
(tail vein) obtained 1, 15, and 30 min after injection as previously reported 
(Somogyi 1945). Skeletal muscles were removed 30 min after the injections. 
Glucose utilization index was determined by measuring the accumulation of 
radiolabeled compound (Ferre, et al. 1985). The amount of 2-DG-6 phosphate 
per milligram of protein was then divided by the integral of the concentration 
ratio of 2-DG to the measured unlabeled glucose. Glucose utilization indexes 
were expressed as picomoles/milligram of protein/minute. 
 
Immunoistochemistry and morphometric analysis 
   PED/PEA-15 antibody has been previously reported (Condorelli, et al. 1998). 
Immunoistochemical detection of PED/PEA-15, insulin and glucagon in 
pancreases from control and transgenic mice were analysed as described 
(Vigliotta, et al. 2004). Analysis of serial consecutive islet sections stained with 
either insulin or PED/PEA-15 antibodies was used to confirm ped/pea-15 
expression in insulin-immunopositive beta cells. Sections were also stained 
with hematoxylin and eosin. For morphometry, pancreases were obtained from 
6-month-old control and transgenic mice, and immunohistochemical detection 
of insulin was performed in 3 sections (2-3 µm) separated by 200 µm as in 
(Devedjian, et al. 2000).  
 
Islet isolation, ex vivo insulin secretion assessment 
   Islets were isolated from 6-month-old mice by collagenase digestion and 
subsequent centrifugation on a Histopaque (Sigma-Aldrich, MO) gradient as in 
(Kitamura, et al. 2001). 20 islets were manually selected and preincubated in 
Dulbecco’s modified Eagle’s medium (DMEM, Life Technologies, Germany) 
at 37°C in a 5% CO2 atmosphere for 24 hours. Islets were then further 
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incubated in Krebs-Ringer Buffer (KRB, 120 mM NaCl, 1.2 mM MgSO4, 5 
mM KCl, 10 mM NaHCO3, 1.3 mM CaCl2, 1.2 mM KH2PO4) for 30 min, and 
then stimulated at 37°C with various concentrations of either glucose for 1 
hour, KCl for 30 min, or glyburide (Sigma-Aldrich, MO) for 1 hour. Islets 
were subsequently collected by centrifugation and supernatants were assayed 
for insulin content by RIA.  
 
Cell culture procedures and transfection.  
   MIN-6 cells were cultured in DMEM containing 25 mM glucose, 50 µM 2-
mercaptoethanol, and 10% fetal calf serum (Biochrom, Germany) at 37°C in a 
5% CO2 atmosphere (Miyazaki, et al. 1990). INS-1 cells were cultured in 
RPMI 1640 medium (Life Technologies, Germany) containing 11 mM glucose, 
50 µM 2-mercaptoethanol, and 10% fetal bovin serum (Biochrom, Germany) at 
37°C in a 5% CO2 atmosphere (Wang, et al. 2002). Stable transfection of the 
ped/pea-15 cDNA was performed with the lipofectamine method according to 
manufacturer’s instructions. Transient transfection of the PKCzetacDNA was 
also performed with the lipofectamine method. By using PCAGGS-β-Gal as a 
reporter, transfection efficiency was between 65 and 85%, staining with the 
chromogenic substrate 5-bromo-4-chloro-3-indolyl b-D-galactopyranoside.  
 
RNA extraction and Real-Time RT-PCR analysis.  
   Total cellular RNA was isolated from pancreatic islets and tissue samples by 
using the RNeasy kit (QIAGEN Sciences, Germany), and from white blood 
cells were immediately extracted following cell isolation using the QIAamp 
RNA Blood Mini Kit according to the manufacturer’s instructions. For Real-
time RT-PCR analysis, 1 µg of islet or cell RNA was reverse-transcribed using 
Superscript II Reverse Transcriptase (Invitrogen, CA). PCR reactions were 
analyzed using SYBR Green mix (Invitrogen, CA). Reactions were performed 
using Platinum SYBR Green qPCR Super-UDG using an iCycler IQ multicolor 
Real Time PCR Detection System (Biorad, CA). All reactions were performed 
in triplicate and β-actin was used as an internal standard. 
 
Western blot analysis and PKC assay.  
   Tissues homogenates and cell lysates were separated by sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and analysed by 
western blot as previously described (Vigliotta, et al. 2004; Laemmli 1970). 
Membranes were probed with antibodies to PED/PEA-15, PKCζ (Santa Cruz 
Biotechnology, Inc., CA), or tubulin (Santa Cruz Biotechnology, Inc., CA). For 
analyzing atypical PKC activity, cells were incubated with KRB for 30 min 
and then incubated with either 2.8 or 16.7 mM glucose containing medium for 
1h at 37°C in a 5% CO2 atmosphere. Cells were solubilized in lysis buffer (25 
mM Tris-HCL, pH 7.4, 0.5 mM EDTA, 0.5 mM EGTA, 0.05% Triton X-100, 
10 mM beta-mercaptoethanol, 1mg/ml leupeptin, 1 mg/ml aprotinin) for 1 h at 
4°C. Lysates were precipitated with a PKCzeta antibody and PKC activity was 
assayed using the SignaTECTTM PKC assay system (Promega, WI), according 
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to manufacturer’s instructions. Determination of PKC activity using the Ac-
MBP(4-14) or the pseudosubstrate region of PKCepsilon (specific for atypical 
PKC) provided consistent results. 
 
Statistical procedures.  
   Data were analysed with Statview software (Abacus-concepts) by one-factor 
analysis of variance. p values of less than 0.05 were considered statistically 
significant (Vigliotta, et al. 2004). 
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Results and discussion 
 
   As I mentioned before, the hyper-expression of Phosphoprotein Enriched in 
Diabetes/Phosphoprotein Enriched in Astrocytes gene is commonly found in 
human diabetic patients. Previous studies in humans, indeed, have reported that 
PED/PEA15 gene is overexpressed in skeletal muscle and fat tissues as well as 
in cultured skin fibroblasts from individuals with T2D, and this effect occurs 
independently of obesity and drug treatment (Condorelli, et al. 1998), 
suggesting that it may be a primary component of insulin resistance in these 
subjects.  
   In this context, I investigated whether PED/PEA15 overexpression occurs in 
individuals at high risk of diabetes and whether it is associated with specific 
T2D subphenotypes. 
   I addressed these questions by measuring PED/PEA-15 protein and mRNA 
expression levels in First Degree Relatives (FDR) of T2 diabetic subjects. These 
individuals have a very high risk of T2D and develop different diabetes-related 
phenotypes years before diabetes onset, independently of the metabolic 
abnormalities associated with this disorder. PED/PEA15 levels were measured 
in the Peripheral Blood Leucocytes (PBLs) of these individuals. Indeed, 
PED/PEA-15 levels in PBLs are closely correlated with those in fat and skeletal 
muscle tissues. Thus, although PBLs do not represent a classical target for 
insulin, they represent a non-invasive investigation to quantify PED/PEA15 
expression. 
   In FDR-subjects, there was a two-fold increase both in PED/PEA-15 protein 
and mRNA levels compared to control euglycaemic individuals (Eu) (p<0.001; 
Figure 9a, b), suggesting that PED/PEA-15  overexpression is caused, at least in 
part, by a transcriptional abnormality. Furthermore, this increase was of a 
similar magnitude to that observed in a group of T2 diabetic patients. As in the 
case of T2 diabetic patients, one-third of the FDR-subjects expressed amounts 
of PED/PEA15 protein that were more than two SDs higher than the mean for 
the Eu-subjects. It appears therefore that increased PED/PEA15 levels represent 
a common abnormality in both T2 diabetic subjects and individuals at increased 
risk of this disease, suggesting that it might precede diabetes onset. 
   To address the functional significance of PED/PEA15 overexpression in T2 
diabetic FDR, we searched for associations with diabetes-related phenotypes. 
We analysed a group of 25 euglycaemic offspring of T2D-affected couples. 
PBL expression levels of PED/PEA15 in these offspring were comparable to 
those of the other T2 diabetic FDR investigated previously (Table 4). A 
negative correlation was evidenced between the individual levels of 
PED/PEA15 in PBLs and insulin-stimulated glucose disposal according to fat-
free mass, as determined by the euglycaemic–hyperinsulinaemic clamp (r=-557, 
p=0.01; Figure 10), suggesting that high levels of PED/PEA15 protein 
contribute to development of skeletal muscle resistance to insulin action in these 
individuals. Furthermore, PED/PEA15 levels were also weakly correlated with 
fasting plasma insulin in these FDR, but not in euglycaemic individuals lacking 
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a family history of type 2 diabetes. By contrast, in these FDR, PED/PEA15 
levels were not related to BMI, waist circumference, systolic and diastolic blood 
pressure, HDL cholesterol, triacylglycerol and glucose levels, indicating that 
expression of the PED/PEA15 gene is independent of the main variables 
associated with the metabolic syndrome in humans, and they were not related to 
age, or to reduced physical activity, two recognised risk factors for T2D and 
insulin resistance. 
 
 
Figure 9 Expression of PED/PEA15 in PBLs from euglycaemic subjects.  
PBLs from euglycaemic individuals with at least one T2 diabetic FDR (EuF+) and euglycaemic 
subjects lacking a family history of diabetes (EuF-) were consecutively collected. For 
comparison, PBLs from T2 diabetic patients (T2D) were also analysed. Cells were solubilised 
and PED/PEA15 protein (a) and mRNA levels (b) were quantified. 
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Table 4 Clinical and biochemical features of the type 2 diabetic offspring 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data are presented as the means ± SEM 
HOMA-B Homeostasis model assessment of pancreatic beta cell function, HOMA-IR 
homeostasis model assessment of insulin resistance, LBM lean body mass 
    
Thus, in euglycaemic FDR of T2 diabetic patients, high PED/PEA15 levels are 
strongly correlated with resistance to insulin action in the lean mass, suggesting 
that PEA15 contributes to the early appearance of insulin resistance in these 
individuals.  
 
 
Figure 10 Risk-factors related to PED/PEA15 expression. 
PED/PEA15 protein levels were determined in PBLs from 25 euglycaemic offspring of couples, 
one of which was affected by T2D. Glucose disposal was assessed by the euglycaemic–
hyperinsulinaemic clamp as described in material and methods section and corrected for fat-
free mass. 
Parameter  Mean ± SEM 
Number (male/female)  
Age (years)  
BMI (kg/m2)  
Waist circumference (cm)  
Systolic BP (mmHg)  
Diastolic BP (mmHg)  
Total cholesterol (mmol/l)  
HDL cholesterol (mmol/l)  
Triacylglycerol (mmol/l)  
Fasting plasma glucose (mmol/l)  
2-h glucose (mmol/l)  
Fasting plasma insulin (pmol/l)  
Fat-free mass glucose disposal (mg kg LBM-1 min-1)  
HOMA-IR  
HOMA-B  
Insulinogenic index (∆I30/∆G30)  
PEA15 (arbitrary units)  
13/12 
30.1±8.3 
24.5±4.1 
83.5±12.2 
112±11 
75±6 
4.8±0.9 
1.5±0.3 
1±0.7 
4.8±0.5 
5.8±1.4 
55.6±20.8 
12±3 
1.8±0.9 
174±65 
18±12 
257±35 
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   Nevertheless, PED/PEA15 levels were not correlated with any index of beta 
cell function in the offspring. Overexpression of the gene may impair glucose-
triggered insulin secretion in transgenic mice but not in humans. This is 
unlikely, however, as transfection of a PED/PEA15 cDNA in human beta cell 
lines grossly impairs the insulin response to glucose. Alternatively, in the T2 
diabetic FDR, the consequence of the high PED/PEA15 levels on insulin action 
might occur earlier during life than the PED/PEA15 effect on beta cell 
function. 
 
   To investigate the relevance of PED/PEA-15-induced beta cell dysfunction to 
glucose tolerance, I generated and characterized a transgenic mouse featuring 
selective overexpression of PED/PEA-15 in the beta cells (beta-tg). To this 
aim, the entire human ped/pea-15 cDNA was cloned under the control of the 
RAT Insulin promoter (RIP I), that allows a beta cells specific expression of 
the transgene. 
   I obtained three lines of beta-tg mice (L5, L8, and L9) in which PED/PEA-15 
protein and mRNA showed a 10 to 20-fold increased expression in the 
pancreatic islets compared to their non-transgenic littermates (c) (Figure 11a, 
b); by contrast there were no difference in PED/PEA-15 expression between 
beta-tg and controls in the other tissues taken in account such as the skeletal 
muscle, the liver and the adipose tissue. Moreover, beta-tg mice, were fertile 
and generated viable offsprings showing no significant growth alterations or 
other apparent abnormalities compared to controls. 
   First of all, I studied the glucose homeostasis of beta tg-mice, analysing their 
blood glucose levels and their glucose tolerance. Beta-tg mice, both male and 
female, exhibited slightly reduced fasting blood glucose levels compared to 
control mice (males, 84 ± 6 vs. 91 ± 7 mg/dl; females, 82 ± 8 vs. 92 ± 6 mg/dl; 
significant at the p < 0.05 level). However, during a glucose tolerance test 
(GTT), glucose loading (2 g/kg) rendered the beta-tg mice significantly more 
hyperglycemic during the following 120 min compared to control mice (Figure 
12), suggesting the presence of a severe impairment of glucose tolerance.    
Furthermore, gender and aging (3 to 14 months) had no effect on the 
impairment of glucose tolerance caused by beta cell overexpression of 
PED/PEA-15. This indicates that the selective overexpression of PED/PEA-15 
in beta cell is sufficient to impair glucose tolerance in mice. 
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Figure 11 - PED/PEA-15 expression in beta-tg mice 
Tissues from three lines of beta-tg mice (L5, L8, L9) and from their non transgenic littermates 
(C) were subjected to Northern (a) or Western (b) blotting. Northern blots (30 µg of RNA/lane) 
were probed with ped/pea-15  cDNA. Loading of the same amount of RNA in each lane was 
ensured by further blotting the filters for beta-actin. Quantitation was performed by densitometric 
analysis. Data are plotted as increase of ped/pea-15 mRNA expression in transgenic versus 
control mice. For Western blotting, tissue lysates (100 µg of proteins/lane) were blotted and 
incubated with the PED/PEA-15 antiserum. The autoradiographs shown are representative of 5 
(top) and 6 (bottom) independent experiments. 
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Figure 12 Glucose tolerance in beta-tg mice.  
Three-month-old beta-tg (beta-tg)  mice and their non transgenic littermates (C) were fasted for 
16 h and subjected to IP glucose loading (2 g/kg of body weight). Blood glucose levels were 
determined before and at the indicated times following the load. Values are expressed as 
means ± SD. Asterisks denote statistically significant differences (*, p < 0.05; **, p < 0.01).     
Then, to verify whether beta cell overexpression of PED/PEA-15 is 
accompanied by reduced insulin sensitivity, I performed insulin tolerance tests. 
After intraperitoneal injection of insulin (0.75 mU/g), blood glucose levels 
were comparable between beta-tg and control mice (Figure 13), with no 
significant difference in glucose areas under the curve between beta-tg and 
control mice (C: 9180 ± 1900 mg/dl/120 min; beta-tg: 8805 ± 1600 mg/dl/120 
min). Furthermore, beta-tg mice featured no significant differences in fasting 
nonesterified free fatty acid and triglyceride blood concentrations compared to 
their controls (FFAs: 0.82 ± 0.03 mmol/l vs. 0.78 ± 0.05 mmol/l; Triglyceride: 
115 ± 7 mg/dl vs. 111 ± 8 mg/dl). Moreover, insulin-dependent glucose uptake 
in quadriceps and tibialis muscles from beta-tg and control mice exhibited no 
difference, suggesting that beta-tg mice present an intact insulin sensitivity.  
 
Figure 13 Insulin sensitivity in beta-tg mice. 
Three-month old random-fed beta-tg mice and their non transgenic littermates (C) (n = 
12/group; 6M, 6F) were injected intraperitoneally with insulin (0.75 mU/g of body weight), 
followed by determinations of blood glucose levels at the indicated times. Blood glucose levels 
were determined before and at the indicated times following the load. Values are expressed as 
means ± SD. 
C
beta-tg
B
lo
od
 G
lu
co
se
 (m
g/
dl
) 
15 30 45 60 90 120 
Time after insulin injection (minutes) 
0
40
80
120 
160 
0
C
beta-tg 
Time after glucose loading (minutes)
B
lo
od
 G
lu
co
se
 (m
g/
dl
) 
0
100 
200 
300
400 
500
15 30 60 90 120 
** 
** 
** 
** 
** 
0 
 36
 
   I than investigated: i) the effect of beta cellular PED/PEA-15 overexpression 
on beta-tg insulin secretion in vivo and in vitro; and ii) on their islets 
morphometry.  
   i) Concerning glucose induced insulin secretion, the control mice presented a 
7-fold increase in insulin secretion 3 min after intraperitoneal glucose injection, 
and their levels remained higher than baseline values for up to 30 min, 
indicating a second phase response (Figure 14); by contrast beta tg mice 
presented a 80% increase of fasting insulin levels compared to controls (0.31 ± 
0.07 ng/ml vs. 0.17 ± 0.03, p < 0.001), and they have no significant insulin 
secretion in response to glucose either at 3 or at 30 minutes. Indeed, both their 
acute first-phase insulin secretory response to glucose and their second phase 
response were significantly impaired compared to control mice (p < 0.001). 
Thus, in vivo, isolated beta cell overexpression of PED/PEA-15 increases 
fasting insulinemia but impairs further insulin secretion response to 
hyperglycemia.  
 
Figure 14 Insulin secretion in vivo. 
Beta-tg and control mice (C) were fasted overnight and then injected with glucose (3 g/kg of 
body weight) intraperitoneally. Serum insulin concentrations were measured at the indicated 
times by radioimmunoassay. Data points represent the mean ± SD. Asterisks denote statistically 
significant differences (*, p < 0.05; ***, p < 0.001). 
 
   Then, to clarify the role of PED/PEA-15 overexpression in the impairing of 
glucose induced insulin secretion, I evaluate the insulin secretion in isolated 
pancreatic islets of beta-tg mice. In particular I analysed the insulin secretion 
induced by high glucose levels and by potassium chloride. Similar as in intact 
mice, beta-tg mouse islets exhibited a 2-fold increased insulin release when 
incubated in medium containing 2.8 mM glucose compared to control islets 
(Figure 15a; p < 0.001). Furthermore, raising glucose concentration did not 
further increase the insulin release by these islets, while enhancing that from 
control mice by 3.9-fold (p < 0.001). At variance with glucose, exposure to the 
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comparable release of insulin by both the beta-tg and the control islets (Figure 
15), suggesting that PED/PEA-15 action on glucose-induced secretion affects 
earlier events of beta cell response to glucose upstream the membrane 
depolarisation step.  
 
Figure 15 Insulin secretion ex vivo. 
Islets were isolated from 6-month old mice from the beta-tg and their non transgenic littermates 
(C). Insulin release was determined upon exposure to the indicated concentrations of glucose, 
potassium chloride as described in materials and methods. Bars represent the means ± SD. 
Asterisks denote statistically significant differences (**, p < 0.01). 
 
   ii) Concerning islet morphometry, I found that PED/PEA-15 overexpression 
determines islet hyperplasia with a specific increase in beta cell mass. Indeed, 
beta-tg islets were larger and showed a more elongated and irregular shape but 
featured normal distribution of alpha and beta cells as compared to control 
islets. Quantitative morphometry revealed a 2-fold increase in islet and beta 
cell mass per unit of total pancreatic area in the beta-tg mice (p < 0.01; Table 
5) with no significant difference in their pancreas weight. This may result from 
a direct effect on beta cell survival as PED/PEA-15 exerts a broad anti-
apoptotic action, and it may suggest that the increased beta cell mass observed 
may be responsible for the increased fasting serum insulin levels detected in 
the beta-tg mice.  
 
 
Table 5 Morphometric analysis of beta-tg pancreas 
 Control beta-tg 
% islet area/pancreatic area 0.52 ± 0.06 1.04 ± 0.11  ** 
% beta cells/islet 76.87 ± 4.66 81.33 ± 2.08  * 
% alpha cells/islet 17.23 ± 1.92 14.54 ± 1.85  n.s. 
% other cells/islet 5.90 ± 0.71 4.13 ± 0.41  n.s. 
Pancreas weight (mg) 182 ± 16 188 ± 12  n.s. 
Islet cell mass (mg) 0.95 ± 0.08 1.96 ± 0.06 ** 
Beta-cell mass (mg) 0.73 ± 0.05 1.59 ± 0.06  ** 
 
Mice were analyzed as described in materials and methods. Data are the means ± SD of 
determinations in six beta-tg and six control (non transgenic littermates) mice. * and ** denote 
statistically significant differences, respectively at the p < 0.05 and 0.01 levels. 
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   Thus, this first part of results shows that beta-tg mice present grossly 
impaired glucose tolerance and reduced insulin secretion in response to 
hyperglycemia. This latter defect is comparable to that occurring in mice with 
PED/PEA-15 ubiquitous overexpression (Vigliotta, et al. 2004), suggesting that 
beta cell overexpression of PED/PEA-15 is sufficient to impair glucose 
tolerance in mice. 
   To gain further insights into the mechanisms leading to dysfunction of beta 
cells overexpressing PED/PEA-15, I evaluated the expression of several genes 
relevant to the glucose sensory apparatus by real-time RT-PCR analysis of total 
RNA isolated from islets of beta-tg mice.  
   The amounts of mRNAs for the Sur1 and Kir6.2, the ATP-sensitive K+ 
channel subunits, and the Sur1/Kir6.2 upstream regulator Foxa2 were reduced 
by 30-35% in the islets from beta-tg  compared with those in control mice (p < 
0.001; Figure 16a). Furthermore, islets from beta-tg mice exhibited no 
secretory response to the K+ channel locking agent glyburide (Figure 16b), 
suggesting that PED/PEA-15 overexpression in beta cells induces impairing of 
glucose induced insulin secretion reducing both the expression and the function 
of the channel. At variance, the abundance of glucokinase, HK1, HK2, and 
GLUT2 mRNAs, genes encoding key components of the glucose-sensitive 
insulin secretion machinery were unaffected by PED/PEA-15 in both 
transgenic and control mice (Figure 16a). 
 
 
 
Figure 16 Gene expression profile and glyburide induced insulin secretion in 
isolated islets from beta-tg and controlmice. 
a) The abundance of mRNAs for the indicated proteins was determined by real-time RT-PCR 
analysis of total RNA isolated from islets of beta-tg mice and their non transgenic littermates, 
using beta-actin as internal standard. The mRNA levels in beta-tg islets are relative to those in 
control animals (C). Each bar represents the mean ± SD. Asterisks denote statistically 
significant differences (*, p < 0.05; **, p < 0.01). b) Islets were isolated from 6-month old beta-tg 
and their non transgenic littermates mice (C). Insulin release was determined upon exposure to 
10 µM glyburide. Bars represent the means ± SD. Asterisks denote statistically significant 
differences (*, p < 0.05). 
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   Previous studies in mice evidenced that ablation of either the Sur1 or the 
Kir6.2 genes results in a phenotype reminiscent of that characterizing the beta-
tg mice (Miki, et al. 1998; Nenquin, et al. 2004; Seghers, et al. 2000). Indeed, 
both the Sur1-/- and the Kir6.2-/- mice feature blunted insulin secretion response 
to sulfonylureas, and impaired glucose tolerance and glucose-induced first and 
second phase insulin secretion. Furthermore, fasted Sur1-/- mice are more 
hyperinsulinemic than control animals due to persistent activation of voltage-
gated calcium channels (Nenquin, et al. 2004; Seghers, et al. 2000). Thus, at 
least in part, the loss of potassium channels caused by beta cell overexpression 
of PED/PEA-15 may account for the abnormalities in basal and glucose-
stimulated insulin secretion and in glucose tolerance observed in the beta-tg 
mice.  
   As in the mouse islets, the same results were obtained in the glucose-
responsive MIN-6 and INS-1 beta cell lines upon transfection with ped/pea-15 
cDNA (Min-6ped/pea-15, INS-1ped/pea-15). A close to 35% decrease in the 
abundance of the Sur1, Kir6.2 and Foxa2 mRNAs has been observed compared  
to control cells (p < 0.001). These changes were accompanied by a 
significantly greater release of insulin when in low-glucose medium (2.8 mM 
glucose) with no further insulin secretion upon exposure to 16.7 mM glucose  
(p < 0.001).  
   Recent evidence in skeletal muscle and in fat indicated that high cellular 
levels of PED/PEA-15 impair the function of the atypical PKC isoform 
PKCzeta through a phospholipase D-mediated mechanism. Furthermore, 
atypical PKCs have been reported to control the function of a number of 
transcription factors (Furukawa, et al. 1999; Matsumoto, et al. 2003). In 
particular, very recent data by Hashimoto evidenced that, in PKClambda null 
mice, the expression of Foxa2, Sur1 and Kir6.2 mRNA in the pancreatic beta 
cells is significantly reduced (Hashimoto, et al. 2005). Thus, I evaluated 
glucose induced PKCzeta activity in beta cells overexpressing PED/PEA-15 
and in mouse islets. In both mouse islets and cultured beta cell lines, the effect 
of glucose on insulin release was paralleled by a 2-fold increase in 
immunoprecipitated PKCzeta activity, with no measurable change in its 
expression (Figure 17). By contrast, the effect of glucose was almost 
completely abolished in cells overexpressing PED/PEA-15 and in the beta-tg 
mouse islets, suggesting an important role of atypical PKCs in regulating genes 
of the insulin secretion pathway.  
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Figure 17 PKCzeta activity in beta cell lines overexpressing PED/PEA-15. 
Islet from beta-tg and control mice (right) and wild-type MIN-6 cells and those stably expressing 
the ped/pea-15 cDNA  (MIN-6ped/pea-15; left) were exposed to 16.7 mM glucose for 60 min. 100 
µg of proteins were then precipitated with PKCzeta antibody and PKC activity was assayed as 
described under Research design and methods. PKC activity is expressed as fold-increase over 
basal activity (measured in the presence of 2.8 mM glucose). Bars represent the mean ± SD. 
For control, aliquots of the cell lysates were normalized for protein and directly blotted with 
PKCzeta antibodies. Asterisks indicate statistically significant differences (*, p < 0.05). 
 
   To further analyze this issue, the expression of PKCzeta was forced in the 
MIN-6ped/pea-15 and the INS-1ped/pea-15 cells. The overexpression largely rescued 
PKCzeta activity in the precipitates from glucose-exposed PED/PEA-15 
overexpressing cells (Figure 18a), and this rescue was accompanied by 
recovery of the Sur1, Kir6.2 and Foxa2 gene expression (Figure 18b), and in 
part by a recovery of glucose-induced insulin secretion (Figure 18c), indicating 
that the changes in atypical PKC function caused by PED/PEA-15 
overexpression represent upstream abnormalities impairing the function of 
multiple genes involved in regulating insulin secretion by the beta cell. 
 
 
 
 
 
 
 
 
PK
C
ze
ta
 s
pe
ci
fic
 a
ct
iv
ity
 
(fo
ld
ov
er
ba
sa
ll
ev
el
s)
0
1
2
C beta-tg 
* *
MIN-6ped/pea-15 MIN-6 
PKCzeta 
 41
 
 
 
 
Figure 18 Rescue of PKCzeta activity, gene expression profile and glucose-
stimulated insulin secretion in MINped/pea-15 cells. 
a) MIN-6ped/pea-15 cells were transiently transfected with a PKCzeta cDNA, solubilized and 
lysates immunoprecipitated with a PKCzeta antibody. PKC activity was assayed in the 
immunoprecipitates. For control, aliquots of the lysates were blotted with the PKCzeta antibody 
(inset). Bars represent the means ± SD; b) the abundance of mRNAs for the indicated proteins 
was determined by real-time RT-PCR analysis of total RNA isolated from MIN-6 and MIN-
6ped/pea-15 cells. Bars represent the mRNA levels in the MIN-6ped/pea-15 cells and are relative to 
those in the untransfected cells (MIN-6). Data are expressed as means ± SD; c) the MIN-
6ped/pea-1, either those transiently transfected with the PKCzeta cDNA and the untransfected 
cells, were exposed to 16.7 mM glucose for 60 min and insulin release in the culture medium 
was assayed by radioimmunoassay. Bars represent the means ± SD. Asterisks indicate 
statistically significant differences (*, p < 0.05). 
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feature no PED/PEA-15 expression in beta cells. Islets from these animals 
evidenced a 2-fold increased PKCzeta activation following glucose exposure, 
as compared to islets from control mice (p < 0.01; Figure 19a). The enhanced 
PKCzeta activity is accompanied by 45% increases in the abundance of Kir6.2, 
Sur1 and Foxa2 mRNAs (p < 0.001; Figure 19b), and by a significant 2-fold 
increase in sensitivity to glucose induced insulin secretion compared to 
controls (p < 0.01; Figure 19c). These data evidence that PKCzeta activation is 
sufficient to upregulate these genes, indicating that these genes represent major 
effectors through which PED/PEA-15 physiologically controls insulin 
secretion. 
   Thus, Foxa2-mediated control of glucose sensitivity represents a 
physiological function of PED/PEA-15 in the beta cell, and dysregulation of 
this mechanism may be relevant for Type 2 Diabetes in humans. 
 
 
Figure 19 PKCzeta activity, insulin secretion and gene expression profile in 
isolated islets from KO-PED  mice. 
a) PKC activity was assayed in islets isolated from 6-month old ped/pea-15 null mice (KO) and 
from their unmodified littermates (C), and it is expressed as fold-increase over basal activity; b) 
the abundance of mRNAs was determined by real-time RT-PCR analysis of total RNA isolated 
from islets of KO-PED and control mice using beta-actin as internal standard; c) islets from KO-
PED and control mice were exposed to glucose and potassium. Insulin release is expressed as 
fold-increase in medium insulin concentration over the basal; bars represent the mean ± SD 
Asterisks denote statistically significant differences (**, p < 0.01; ***, p < 0.001). 
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Conclusions 
 
   From the first part of experiments (work in human), I can conclude that 
PED/PEA15 overexpression represents not only a common abnormality in T2 
diabetic patients, but also in their First Degree Relatives. In these individuals, 
PED/PEA15 levels are strongly correlated with resistance to insulin action in 
the lean mass, suggesting that PED/PEA15 contributes to the early appearance 
of insulin resistance.  
   From the second part of experiments (work in mice), I can conclude that 
PED/PEA-15 can be considered as an endogenous regulator of glucose-induced 
insulin secretion, which restrains potassium channel expression in pancreatic 
beta-cells. Indeed, Foxa2-mediated control of glucose sensitivity represents a 
physiological function of PED/PEA-15 in the beta cell, and dysregulation of 
this mechanism is sufficient to impair glucose tolerance in mice, and it may be 
relevant for T2D in humans. 
   We might hypothesize that in T2 diabetic FDR the consequence of the high 
levels of PED/PEA15 on insulin action might occur earlier during life than the 
effects of PED/PEA15 on beta cell function. Thus, follow-up studies of FDR 
individuals are necessary to further elucidate the effect of PED/PEA15 levels 
in the progression to T2D. 
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Raised expression of the antiapoptotic protein ped/pea-15 increases
susceptibility to chemically induced skin tumor development
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ped/pea-15 is a cytosolic protein performing a broad
antiapoptotic function. We show that, upon DMBA/TPA-
induced skin carcinogenesis, transgenic mice overexpres-
sing ped/pea-15 (Tgped/pea-15) display early development of
papillomas and a four-fold increase in papilloma number
compared to the nontransgenic littermates (Po0.001).
The malignant conversion frequency was 24% for the
Tgped/pea-15 mice and only 5% in controls (Po0.01). The
isolated application of TPA, but not that of DMBA,
was sufﬁcient to reversibly upregulate ped/pea-15 in both
untransformed skin and cultured keratinocytes. ped/pea-
15 protein levels were also increased in DMBA/TPA-
induced papillomas of both Tgped/pea-15 and control mice.
Isolated TPA applications induced Caspase-3 activation
and apoptosis in nontransformed mouse epidermal tissues.
The induction of both Caspase-3 and apoptosis by TPA
were four-fold inhibited in the skin of the Tgped/pea-15
compared to the nontransgenic mice, accompanied by a
similarly sized reduction in TPA-induced JNK and p38
stimulation and by constitutive induction of cytoplasmic
ERK activity in the transgenics. ped/pea-15 expression
was stably increased in cell lines from DMBA/TPA-
induced skin papillomas and carcinomas, paralleled by
protection from TPA apoptosis. In the A5 spindle
carcinoma cell line, antisense inhibition of ped/pea-15
expression simultaneously rescued sensitivity to TPA-
induced Caspase-3 function and apoptosis. The antisense
also reduced A5 cell ability to grow in semisolid media by
65% (Po0.001) and increased by three-fold tumor
latency time (Po0.01). Thus, the expression levels of
ped/pea-15 control Caspase-3 function and epidermal cell
apoptosis in vivo and determine susceptibility to skin
tumor development.
Oncogene (2005) 24, 7012–7021. doi:10.1038/sj.onc.1208871;
published online 25 July 2005
Keywords: ped/pea-15; transgenic mice; chemical carcino-
genesis; skin cancer; apoptosis
Introduction
There is evidence that deregulation of apoptosis plays an
important role in tumorigenesis. Indeed, alterations of
apoptosis-related genes have been identiﬁed in a number
of human cancers (Debatin and Krammer, 2004). ped/
pea-15 is a 15 kDa, death effector domain (DED)-
containing protein featuring ubiquitous expression, and
originally identiﬁed as a major astrocytic phosphopro-
tein (Araujo et al., 1993; Condorelli et al., 1998). ped/
pea-15 exerts a broad antiapoptotic action through at
least three distinct mechanisms. Firstly, it inhibits the
formation of the death-inducing signaling complex
(DISC) and Caspase-3 activation triggered by FASL,
tumor necrosis factor alpha, and the tumor necrosis
factor-related apoptosis-inducing ligand (TRAIL) (Con-
dorelli et al., 1999; Kitsberg et al., 1999; Hao et al.,
2001). Secondly, ped/pea-15 inhibits stress-induced
apoptosis by simultaneously blocking stress-activated
protein kinases (SAPK) and increasing the function
of cytosolic extracellular signal-regulated kinases
(ERK1/2) (Condorelli et al., 2002). Thirdly, ped/
pea-15 prevents degradation of the antiapoptotic
protein XIAP caused by release of proapoptotic
mitochondrial proteins (Trencia et al., 2004).
Studies in our own and other laboratories have shown
that elevated expression of ped/pea-15 occurs in several
tumor-derived cell lines. Indeed, ped/pea-15 is highly
expressed in human glioma and metastatic breast cancer
cell lines and induces resistance to chemotherapic agents
in these cells (Ramos et al., 2000; Hao et al., 2001;
Condorelli et al., 2002; Trencia et al., 2004). ped/pea-15
is also expressed at high levels in tumor cell lines derived
from human larynx, cervix, and skin tumors (Condorelli
et al., 1998), and in human mammary carcinomas as
well (Tsukamoto et al., 2000). Finally, the ped/pea-15
gene was demonstrated to be increasingly expressed
during tumor progression in murine squamous carci-
nomas (Dong et al., 2001). However, despite these
mounting evidence supporting the role of ped/pea-15 in
neoplastic transformation and tumor progression,
whether ped/pea-15 has a direct role in tumorigenesis
and progression in vivo has not been investigated yet.
Received 26 January 2005; revised 6 May 2005; accepted 20 May 2005;
published online 25 July 2005
*Correspondence: F Beguinot; E-mail: beguino@unina.it
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Transgenic mice overexpressing ped/pea-15 ubiqui-
tously have recently been generated (Vigliotta et al.,
2004). These mice feature reduced glucose tolerance due
to both impaired insulin action and secretion. We have
now used these transgenics and a well-characterized
mouse model of chemically induced multistep skin
carcinogenesis (Balmain and Harris, 2000) to explore
the role of ped/pea-15 in the initiation, promotion and
progression of skin tumors. Our study shows, for the
ﬁrst time, that ped/pea-15 expression level has a
signiﬁcant impact on skin tumor development in a
mouse model of chemically induced skin carcinogenesis.
Results
Skin carcinogenesis in ped/pea-15 transgenic mice
We have investigated whether the variation in ped/pea-
15 expression levels affects skin tumorigenesis. To this
end, we have used transgenic mice overexpressing the
human cDNA of ped/pea-15 (Tgped/pea-15; Vigliotta et al.,
2004). Based on Western blot analysis, ped/pea-15
protein was overexpressed by about four-fold
(Po0.001) in the epidermis of these transgenics, as
compared to their nontransgenic littermates (WT)
(Figure 1a).
Tgped/pea-15 and control mice (n¼ 40/group; M/F¼ 1)
were subjected to a single DMBA topical application
followed by repeated applications of the tumor promo-
ter TPA. This treatment resulted in the development of
papillomatous lesions. Visible papillomas began to
appear on the dorsal skin of both the Tgped/pea-15 and
WT mice at 7 weeks of promotion, indicating no
difference in the benign tumor latency between the two
groups of mice (Figure 1b). The incidence of papilloma
development reached 100% at 10 weeks of promotion
in the Tgped/pea-15, and at week 12 in the WT mice
(Po0.001; Figure 1b). Interestingly, there was a
signiﬁcant increase in the average number of papillomas
per mouse in the Tgped/pea-15 compared to WT mice
throughout the entire promoter treatment period. The
difference in papilloma number was already signiﬁcant
at week 8. By the end of promotion (week 15), Tgped/pea-15
mice showed 18.4710.7 papillomas per mouse com-
pared to 4.974.8 in the WT mice (Po0.001)
(Figure 1c). No gender-related difference was evidenced
in either the incidence or the number of papillomas in
transgenic and control mice (data not shown).
At 35 weeks after promoter treatment suspension, the
lesions from Tgped/pea-15 and WT mice were subjected to
histological examination. The malignant conversion
frequency was 24% in the Tgped/pea-15 mice (12 out of
50 analysed lesions, Figure 2A). As in previous studies
(Burns et al., 1978), the frequency was only 5% (two out
of 40 analysed lesions) in the control mice (Po0.001),
however. Sections of the lesions from Tgped/pea-15 mice
more frequently showed the presence of a poorly
differentiated epithelial neoplasm composed of nests of
small undifferentiated cells with minimal keratinization,
occasional squamous pearl formation and extremely
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Figure 1 Chemically induced skin carcinogenesis in Tgped/pea-15
mice. (a) Duplicate samples from the dorsal skin of ped/pea-15
transgenic mice (Tgped/pea-15) and the nontransgenic littermates
(n¼ 40 animals/group; male/female¼ 1) were solubilized and
proteins (50mg) analysed by Western blotting with ped/pea-15
antibodies as in Vigliotta et al. (2004). To ensure normalization,
aliquots from the samples were also blotted with tubulin
antibodies. Bars represent the average values (7s.d.) obtained
from ped/pea-15 band densitometry, normalized for tubulin
band densitometry. A representative blot is also shown on the
top. (b and c) Tgped/pea-15 and control mice (three independent
experiments; n¼ 40 animals/group in each; male/female¼ 1) were
subjected to skin carcinogenesis as described under Materials and
methods. The number of papillomas was recorded weekly and is
expressed either as percentage of mice containing at least one
papilloma (b) or the average number (7s.d.) of papillomas per
mouse (c). Statistical signiﬁcance was assessed by t-test analysis
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intense mitotic activity (Figure 2B(c)). As shown in
Figure 2B(d), the majority of the neoplastic cells
displayed intense PCNA nuclear labeling, and stained
cells were scattered throughout the tissue, reﬂecting the
neoplastic modiﬁcations. At variance, lesions from WT
mice more commonly showed benign hyperplastic
proliferation of the epidermis, with epithelial cells
featuring normal morphological characteristics, without
signiﬁcant nuclear atypia (Figure 2B(a)). Based on
PCNA immunostaining, cycling cells were present only
at the basal epidermal level (Figure 2B(b)). Differentiat-
ing squamous cells exhibited no staining, consistent with
lack of dysplatic/neoplastic changes in the WT mouse
skin.
ped/pea-15 levels during skin tumor initiation and
promotion
To investigate the signiﬁcance of ped/pea-15 expression
to skin tumor development and malignant progression,
we have ﬁrst analysed ped/pea-15 levels in papilloma-
tous lesions and in the corresponding skin upon
regression of the lesions. Despite the four-fold increase
in the normal skin of Tgped/pea-15 versus control mice,
ped/pea-15 was raised to comparable absolute levels in
papillomas from WT and Tgped/pea-15 mice (Figure 3a).
Immunohistochemical analysis with ped/pea-15 anti-
bodies revealed comparable distribution of ped/pea-15
between the stromal and epithelial components of the
epidermal tissues from transgenic and control mice (data
not shown). After papilloma regression, there were no
longer differences in ped/pea-15 levels between the skin
a b
c d
Mouse line
No. of mice
At 35 weeks 
by the end of 
promotion
No. of 
carcinomas per 
no. of 
papillomas
Frequency of 
malignant 
conversion
Tgped/pea-15 12 12/50 24%
Wt 20 2/40 5%
A
B
Figure 2 Malignant conversion frequency in Tgped/pea-15 mice. (A)
ped/pea-15 transgenic and control mice were subjected to chemical
carcinogenesis as described under Materials and methods. Total
papilloma and carcinoma numbers were recorded. Carcinoma
numbers were scored by morphological appearance on collection
followed by histological conﬁrmation after H&E staining of
parafﬁn sections. (B) Representative H&E stained parafﬁn sections
( 100 magniﬁcation) of tumors at 35 weeks after the end of
promotion treatment from control (a) and Tgped/pea-15 mice (c). In
the transgenics, PCNA immunostaining ( 100 magniﬁcation) was
scattered throughout the the tumour tissue (d), while limited to
the basal cells in the control mice (b), as evidenced at higher
magniﬁcation ( 400). Representative microphotographs are
shown
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Figure 3 ped/pea-15 expression in cell lines from chemically
induced skin tumors and papillomas from Tgped/pea-15 mice.
(a) Papillomatous lesions (P; n¼ 32), samples from unaffected skin
of the surrounding areas (NS; n¼ 34), or from the skin corresponding
to the papillomatous base upon regression of the lesion (R; n¼ 28)
from control (WT) and ped/pea-15 transgenic mice (Tgped/pea-15)
animals (n¼ 27/group) were excised and lysed as described in the
legend to Figure 1. ped/pea-15 and tubulin expression were detected
in the lysates (50mg of proteins/sample) by Western blotting and
autoradiography. Blots were revealed by ECL and autoradiography
and analysed by laser densitometry. Bars represent the average
(values7s.d.) of the tubulin-normalized expression of ped/pea-15 in
duplicate determinations from four independent experiments. The
difference between P and NS was signiﬁcant at the P¼ 0.001 (Wt)
and Po0.001 (Tg). (b) The C5N, P1 and A5 cell lines derived,
respectively, from normal keratinocytes, DMBA/TPA-induced
papillomas and spindle cell carcinomas, were cultured as described
under Materials and methods. Cell proteins (50mg) were Western
blotted with ped/pea-15 or tubulin antibodies as indicated. Blots
were revealed and further analysed as in (a). Bars represent the
average (values7s.d.) of the tubulin-normalized expression of ped/
pea-15 in duplicate determinations from four independent experi-
ments. The difference between the P1 and C5N cells and between the
A5 and C5N cells were signiﬁcant at the Po0.001 level. A
representative autoradiograph is also shown
ped/pea-15 transgenic mice and skin cancer
P Formisano et al
7014
Oncogene
where the lesion had originated and the surrounding
normal skin, in both the Tgped/pea-15 and the WT mice.
We next analysed mouse cell lines derived from
DMBA/TPA-induced skin tumors at different stages
of carcinogenesis (Portella et al., 1998). By Western
blotting, ped/pea-15 protein was similarly overexpressed
(almost three-fold; Po0.001) in both the P1 benign
papilloma cells and the A5 highly anaplastic, invasive
spindle carcinoma cells compared to the C5N immorta-
lized nontumorigenic keratinocytes (Figure 3b). Thus, in
the cell lines as well as in vivo, the increase in ped/pea-15
protein level appeared to occur at an early stage during
skin carcinogenesis.
Repeated applications of the DMBA initiator on the
mouse skin did not change ped/pea-15 levels either
in the Tgped/pea-15 or in WT mice (Figure 4a). Also,
transfection of the constitutively active H-Ras61 mutant
in keratinocytes showed no effect on ped/pea-15 levels
(Figure 4b), indicating that Ras activation is not
sufﬁcient to upregulate ped/pea-15. At variance with
DMBA, TPA treatment raised ped/pea-15 expression in
skin cells, both in the absence and in the presence of the
H-Ras61 mutant (Figure 4b). Indeed, exposure of the
nontumorigenic C5N keratinocytes to 100 mg/ml TPA
increased ped/pea-15 protein level in a time-dependent
manner (Figure 5a). The effect achieved a plateau (ﬁve-
fold increase) within 24 h and was maintained for 24
more hours, returning to baseline upon TPA with-
drawal. Also, a single TPA application to the skin of
both WT and Tgped/pea-15 mice caused a ﬁve-fold
elevation of ped/pea-15 protein for up to 48 h, declining
thereafter and returning to the pretreatment level by
144 h (still four-fold higher in transgenic compared to
WT mice; Figure 5b). Previous studies showed that
phosphorylation by both Akt/PKB and PKC increases
intracellular stability of ped/pea-15 (Trencia et al.,
2003). Based on immunoblotting with speciﬁc pSer116
and pSer104 ped/pea-15 antibodies, these increased ped/
pea-15 levels in TPA-treated skin were accompanied by
2.5- and four-fold increased phosphorylation of ped/
pea-15 on the Akt/PKB and PKC sites (Ser116 and
Ser104, respectively). There were no differences in these
phosphorylations in Wt and transgenic mice suggesting
that increased ped/pea-15 stability may, at least in part,
account for the effect of TPA in these animals
(Figure 5c).
Effect of ped/pea-15 on skin tissue apoptosis
To examine the consequences of ped/pea-15 overexpres-
sion and its role in skin tumorigenesis, we compared
in vivo apoptosis in the skin of Tgped/pea-15 and WT mice
upon the application of TPA. Based on skin lysate
determination, Tgped/pea-15 mice showed a signiﬁcant
decrease in the number of apoptotic cells compared to
WT animals (Figure 6a). Importantly, TPA application
to the skin of WT mice induced the appearance of the
20K fragment of the terminal caspase Caspase-3 in the
lysates, evidencing Caspase-3 activation (Figure 6b).
Activation of Caspase-3 by TPA was barely detectable
in the skin of Tgped/pea-15 mice, however. Consistently,
cleavage of the Caspase-3 substrate PARP was well
evident upon treating WT mouse skin with TPA, but
>10-fold less measurable in Tgped/pea-15 mice
(Figure 6c).
At variance with Caspase-3, TPA treatment exhibited
very little effect on the activation of the upstream
caspase, Caspase-8, in both WT and Tgped/pea-15 mouse
skin (data not shown).
In different cell types, ped/pea-15 protects the
inhibitor of apoptosis XIAP from the intracellular
degradation following certain apoptotic stimuli, thereby
preventing Caspase-3 activation (Trencia et al., 2004).
However, skin lysates from WT and Tgped/pea-15 mouse
showed no difference in XIAP levels (Figure 7a),
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Figure 4 Effect of DMBA application and of constitutively active
Ras mutant on ped/pea-15 expression. (a) Mouse dorsal skin
was treated by repeated DMBA applications at times 0, 6 and 12 h.
ped/pea-15 and tubulin expression was determined at the indicated
times upon the ﬁrst application of DMBA, as described above.
Bars represent the mean7s.d. of duplicate determinations of the
tubulin-normalized expression of ped/pea-15 in 2 (a: n¼ 20 mice/
time point) independent experiments. Representative blots are also
shown in the insets. (b) The C5N cells were transfected with 2.5 or
5.0mg of H-Ras61 or with 5.0 mg of the empty vector (pc) as
described under Materials and methods. After TPA treatment,
cells were lysed and cell proteins (50mg) were Western blotted with
ped/pea-15 or tubulin antibodies as indicated. Blots were revealed
by ECL and autoradiography and analysed by laser densitometry.
Bars represent the average (values7s.d.) of the tubulin-normalized
expression of ped/pea-15 in duplicate determinations from three
independent experiments. Representative blots are also shown in
the insets
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suggesting that alternative mechanisms are responsible
for the reduced apoptosis occurring in the Tgped/pea-15
mouse skin after TPA exposure. Indeed, previous
studies in 293 cells indicated that ped/pea-15 antiapop-
totic function requires ped/pea-15 simultaneous inhibi-
tion of the SAPK signaling system of JNK/p38 and
activation of ERK1/2 (Condorelli et al., 2002). In WT
mouse skin, TPA elicited a 10-fold increase in phos-
phorylation of the key activation sites of JNK (Thr183
and Tyr185) and those of p38 (Thr180, Thr182),
indicating activation of these kinases (Figure 7b).
Interestingly, the effect of TPA was ﬁve-fold reduced
in Tgped/pea-15 mouse skin, despite normal expression of
both JNK and p38. ERK1/2 phosphorylation was also
constitutively increased in Tgped/pea-15 compared to Wt
mouse skin (Figure 7c). Despite the eight-fold induction
in the WT mouse, ERK phosphorylation in response to
TPA showed little further increase in the transgenics,
with no signiﬁcant difference in ERK1/2 expression.
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Figure 5 Effect of isolated applications of TPA on ped/pea-15
expression and phosphorylation. C5N keratinocytes (a) and shaved
dorsal skin of WT and Tg mice (b) were exposed to TPA,
respectively, by addition to the culture medium (a) and topical
application (b) as described under Materials and methods. Upon
48h, TPA was removed from the cell cultures by medium
replacement (a). At the indicated times, cells (a) and tissue samples
(b) were lysed and analysed by Western blotting with ped/pea-15
and tubulin antibodies. Skin lysate ﬁlters were also reblotted with
speciﬁc phosphoserine104 and phosphoserine116 antibodies (c).
Blots were revealed by ECL and autoradiography and subjected
to densitometric quantitation. Bars represent the mean7s.d. of
duplicate determinations of the tubulin-normalized expression of
ped/pea-15 in three (a, b: n¼ 20 mice/time point) and two (c)
independent experiments. Representative blots are also shown in
the insets
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Figure 6 TPA-induced apoptosis and activation of Caspase 3 in
Tgped/pea-15 mice. (a) Transgenic and control mice (n¼ 30/group;
M/F ratio¼ 1 in each group) were subjected to TPA applications
(6.25 mg of TPA in 200ml acetone for 24 h) as described under
Materials and methods. Samples of squamous stratiﬁed epithelium
from the treated areas were solubilized and analysed with the
ELISAPLUS kit for detection of apoptosis. Bars represent the mean
values (7s.d.) of triplicate determinations in three independent
experiments. (b) The dorsal skin of Tgped/pea-15 and control mice
was treated with TPA as above. Samples from the treated skin were
excised and analysed by Western blotting with Caspase-3 (b) or
PARP antibodies (c). Blots were revealed by ECL and autoradio-
graphy. A representative autoradiography is shown; same results
were obtained in three further experiments
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Consistent with the reported ability of ped/pea-15 to
prevent nuclear migration of ERK1/2, phosphorylation
of the ELK substrate in response to TPA was drastically
reduced in tissues from Tgped/pea-15 compared to control
mice. At variance with ELK, TPA phosphorylation of
the H3 histone target of the ERK1/2-downstream and
ped/pea-15 binding kinase RSK2 (Vaidayanathan
and Ramos, 2003) showed no difference in Tgped/pea-15 and
control mice (data not shown). Thus, at least in part,
overexpression of ped/pea-15 may inhibit TPA-induced
apoptosis by dysregulating selective pathways of the
MAPK signaling and by inhibiting Caspase-3.
The role of caspase-3 inhibition in chemically induced
skin tumorigenesis
To further address the involvement of impaired Cas-
pase-3 activation in the increased susceptibility to skin
carcinogenesis of the Tgped/pea-15 mice, we ﬁrst compared
TPA effect in the C5N nontumorigenic mouse kerati-
nocytes and the A5 highly malignant invasive spindle
carcinoma cells. Based on its own cleavage and that of
the PARP substrate, TPA induction of Caspase-3 was
barely detectable in the ped/pea-15 overexpressing A5
cells, despite the evident effect occurring in the C5N
keratinocytes (Figure 8a). The reduced activation of
Caspase-3 in the A5 carcinoma cells was paralleled by a
six-fold decrease in TPA-induced apoptosis, compared
to the C5N keratinocytes (Figure 8b). We then silenced
the expression of ped/pea-15 using a speciﬁc antisense
cDNA (Hao et al., 2001). In the A5 cells, the antisense
inhibited ped/pea-15 expression to levels comparable to
those of the untreated C5N keratinocytes (Figure 8c). In
parallel, the antisense rescued TPA apoptosis in the A5
cells, rendering the A5 as responsive to TPA as the C5N
cells (Figure 8b). Caspase-3 and PARP cleavage in
response to TPA was similarly rescued in antisense-
transfected A5 cells (Figure 8a).
The colony growth rate in semisolid medium was also
reduced in the antisense expressing A5 clones compared
to cells tansfected with the empty vector (65% reduc-
tion; Po0.001) (Table 1). Importantly, injection of A5
cells transfected with either the ped/pea-15 antisense
cDNA or the empty vector into athymic mice showed no
signiﬁcant difference in tumor incidence. However, the
tumor latency period of the antisense expressing clones
was almost three-fold increased compared to that of
control cells (Po0.01).
Discussion
There is evidence that increased expression of the
antiapoptotic protein ped/pea-15 is associated to devel-
opment of malignancy (Condorelli et al., 1998; Ramos
et al., 2000; Tsukamoto et al., 2000; Dong et al., 2001;
Hao et al., 2001). However, no information is available,
to date, to assess whether modulation of ped/pea-15
expression may directly affect tumorigenesis and/or
progression in vivo. Chemically induced skin carcino-
genesis studies have provided valuable information
concerning the impact of genetic alterations on multi-
step tumorigenesis and progression in genetically
modiﬁed mice (Balmain and Harris, 2000). In the
present paper, we have addressed the role of ped/pea-
15 in skin tumor initiation, promotion and progression
and used transgenic mice overexpressing the ped/pea-15
gene. These mice express three- to four-fold higher skin
levels of ped/pea-15 compared to their nontransgenic
littermates. We now report that, in parallel with the
increased ped/pea-15 expression, the transgenics show
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Figure 7 Effects of TPA on XIAP expression and JNK, p38,
ERK1/2 and ELK1 phosphorylations. Transgenic and control mice
(n¼ 12/group; M/F ratio¼ 1 in each group) were subjected to TPA
applications (6.25mg of TPA in 200ml acetone for 24 h) as described
under Materials and methods. Samples from the treated skin were
excised and analysed by Western blotting with XIAP, tubulin (a),
phospho-JNK, JNK, phospho-p38, p38 (b), phospho-ERK1/2,
ERK1/2, phospho-Elk1, and Elk-1 antibodies (c). Blots were
revealed by ECL and autoradiography. The autoradiographs
shown are representative of four (a and b) and three (c)
independent experiments
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anticipated as well as increased occurrence of benign
papillomatous lesions upon being topically treated with
the tumor initiator DMBA followed by repeated
applications of the tumor promoter TPA. Interestingly,
ped/pea-15 expression is also increased in papillomas
from WT mice, compared to the adjacent normal skin.
The signiﬁcance of the increased ped/pea-15 levels to
skin tumorigenesis is further strengthened by the ﬁnding
that, upon papilloma regression, ped/pea-15 returns to
basal levels in the skin where the lesions have been
produced. In addition, the malignant conversion fre-
quency of the papillomatous lesion was signiﬁcantly
higher in ped/pea-15 transgenic compared to the control
animals. These results indicate, for the ﬁrst time, that
increased levels of ped/pea-15 confer greater suscept-
ibility to skin carcinogenesis in vivo and may enhance
cutaneous tumor progression toward malignancy.
Indeed, after suspension of TPA treatment, the trans-
genic mice maintain stably elevated ped/pea-15 levels
compared to the WT animals where the effect of
TPA vanishes.
We show that the constitutively active H-Ras61
mutant does not affect ped/pea-15 expression levels in
keratinocytes. Consistently, DMBA application did not
upregulate ped/pea-15 in mouse skin, indicating that Ras
mutation is not sufﬁcient to cause ped/pea-15 over-
expression. At variance, treatment with TPA alone
rapidly increased ped/pea-15 expression levels in the skin
of both transgenic and control mice, suggesting that
ped/pea-15 overexpression represents an early event
during cutaneous tumor promotion, though not initia-
tion. At least in part, the effect of TPA may be mediated
by induction of PKB/Akt and PKC. Indeed, (i)
phosphorylation of ped/pea-15 on PKB/Akt and PKC
sites is increased in TPA-treated skin; and (ii) previous
studies (Trencia et al., 2003) demonstrated that phos-
phorylation of these sites increases cellular stability of
ped/pea-15. In addition, transformed cell lines derived
from DMBA/TPA-induced skin tumors consistently
show higher ped/pea-15 levels compared to immorta-
lized nontumorigenic keratinocytes. It is conceivable,
therefore, that higher ped/pea-15 levels may confer
a distinctive advantage to the cells upon DMBA
initiation, leading to selection of those overexpressing
ped/pea-15.
Transgenic mice overexpressing ped/pea-15 feature
insulin-resistance and decreased glucose tolerance
(Vigliotta et al., 2004). Considerable epidemiological
evidence exists indicating that these metabolic abnorm-
alities have a role in determining the occurrence of a
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Figure 8 Effect of ped/pea-15 silencing on TPA apoptosis in C5N
and A5 cells. (a) C5N and A5 cells stably transfected with ped/pea-
15 antisense cDNA were obtained as described under Materials
and methods. Antisense-expressing and control cells were exposed
to TPA for 24 h and then solubilized. Cell lysates (50 mg per point)
were then analysed by Western blotting with Caspase-3 or PARP
antibodies, as indicated. The effect of the antisense on ped/pea-15
expression was controlled in the same cell lysates by Western
blotting with ped/pea-15 antibodies as described in the legend to
Figure 3(c). Filters were revealed by ECL and autoradiography.
The autoradiographs shown are representative of three indepen-
dent experiments. Alternatively (b), TPA-stimulated cells were
solubilized and analysed with the ELISAPLUS kit for detection of
apoptosis as described under Materials and methods. Bars
represent the mean values (7s.d.) of triplicate determinations in
three independent experiments
Table 1 Analysis of transformation markers of A5 carcinoma cells
Transfected
DNA/caspase
inhibitor
Colony-forming
efﬁciency (%)a
Tumor
incidenceb
Latency period
(days)c
— 58 5/5 14
pcDNA vector 56 6/6 14
pcDNA AS 20 6/6 39
Z-DEVD-FMK 14 — —
aColonies larger than 64 cells were scored after 3 weeks. Colony-
forming efﬁciency was calculated by dividing the number of colonies
formed by the number of plated cells  100. bTumorigenicity was
assayed by injecting 1 106 cells into 6-week-old athymic mice. CThe
animals were monitored for the appearance of tumors. The mean
tumor latency is the time needed for tumors to reach 10mm in
diameter. The tumor latency of the antisense (AS)-transfected cells
differed signiﬁcantly from controls (Po0.001)
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number of tumors in humans (Calle and Kaaks, 2004).
Transgenic mice overexpressing ped/pea-15 show no
greater prevalence of spontaneous tumors, but whether
insulin-resistance and/or impaired glucose tolerance
contribute to the increased susceptibility to skin
carcinogenesis cannot be concluded from the present
study. Different mechanisms likely play a greater role,
however, as TPA-induced upregulation of ped/pea-15
also accompanies skin tumor development in nontrans-
genic mice featuring normal insulin sensitivity and
glucose tolerance.
ped/pea-15 performs a broad antiapoptotic action in
cultured cells (Condorelli et al., 1999, 2002; Kitsberg
et al., 1999; Hao et al., 2001; Trencia et al., 2004). At
least in part, ped/pea-15 antiapoptotic action is due to
inhibition of the induction of the terminal caspase,
Caspase-3 (Hao et al., 2001; Condorelli et al., 2002). In
this paper, we show that TPA-induced apoptosis in
squamous stratiﬁed epithelium in vivo is also signiﬁ-
cantly inhibited in ped/pea-15 transgenic mice. This
decrease is accompanied by reduced activation of
Caspase-3 and cleavage of the Caspase-3 substrate
PARP in response to TPA. Reduced apoptosis and
Caspase-3 activation in response to TPA also occur in
the A5 cells, which are derived from DMBA/TPA-
induced spindle cell carcinomas and overexpress ped/
pea-15. Consistently, in the normal C5N keratinocytes
that express lower levels of endogenous ped/pea-15,
transfection of ped/pea-15 cDNA and treatment with the
speciﬁc Caspase-3 inhibitor Z-DEVD-FMK prevented
TPA apoptosis in a nonadditive manner (data not
shown). Expression of a speciﬁc ped/pea-15 antisense
cDNA in the A5 cells simultaneously reduced ped/pea-
15 levels and rescued TPA-induced apoptosis and
Caspase-3 activation. Importantly, the antisense signiﬁ-
cantly increased the latency preceding tumor formation
upon A5 cell injection in nude mice. The A5 cell growth
in semisolid medium was also signiﬁcantly reduced by
decreasing ped/pea-15 expression. Thus, the impaired
apotosis determined by inhibition of Caspase-3 activity
in ped/pea-15 overexpressing skin cells might affect the
malignant progression as well as tumorigenesis.
Previous studies by other investigators and by us have
shown that ped/pea-15 may inhibit Caspase-3 function
by preventing the activation of Caspase-8 (Condorelli
et al., 1999; Kitsberg et al., 1999) as well as by increasing
stability of the inhibitor of apoptosis protein XIAP
(Trencia et al., 2004). These events do not account for
ped/pea-15 inhibition of Caspase-3 in TPA-treated skin,
as ped/pea-15 overexpression does not affect TPA action
on either Caspase-8 function or XIAP levels. In certain
cell types, block of the JNK and p38 members of the
MAPK family also plays an important role in mediating
the ped/pea-15 protection from apoptosis (Condorelli
et al., 2002), which may lead to Caspase-3 inhibition
(Kamata et al., 2005). Full antiapoptotic function in
these cells requires concomitant ped/pea-15 induction of
the ERK1/2 MAPKs and/or ERK1/2 anchoring into the
cytoplasm (Formstecher et al., 2001; Condorelli et al.,
2002). Impaired JNK and p38 activation and increased
ERK1/2 cytoplasmic activity have also been detected in
the skin of Tgped/pea-15 mice upon exposure to TPA,
indicating they may mediate the decreased susceptibility
to apoptosis caused by overexpression of ped/pea-15 in
these cells. Indeed, same as in other cell types
(Condorelli et al., 2002), in the A5, the rescue of JNK
function by overexpression of the upstream kinase
MKK6 signiﬁcantly enhanced the apoptotic response
to TPA (data not shown).
Intriguingly, Gaumont-Leclerc et al. (2004) have very
recently reported evidence that ped/pea-15 may exert a
tumor suppressor function in the IMR90 ﬁbroblasts. It
is possible that this function is also exerted in the mouse
keratinocyte model. Upon DMBA/TPA exposure of
these cells, the antiapoptotic function of ped/pea-15
seems to prevail, however. Consistently, ped/pea-15
overexpression confers raised susceptibility to chemical
carcinogenesis in the skin. Thus, different settings may
lead ped/pea-15 to have its pro- or antioncogenic
functions overriding.
Deregulated apoptosis has been suggested to play an
important role in tumorigenesis and malignant progres-
sion of transformed cells by contributing the cells with
the capability to skip cell death programs, accumulating
DNA damage (Debatin and Krammer, 2004). In certain
tumors, these abnormalities may occur because of loss
of proapoptotic molecules such as Bax, Apaf-1 or
Caspase-8 (Harada and Grant, 2003; Baldi et al., 2004).
In other situations, impaired apoptosis has been
associated to increased expression of antiapoptotic
molecules of the Bcl-2 family (Harada and Grant,
2003). In this paper, we have shown that increased
expression levels of the antiapoptotic protein ped/pea-15
may also determine susceptibility to skin tumorigenesis
and tumor progression by inhibiting Caspase-3-depen-
dent apoptosis in DMBA/TPA-treated mice. Several
alterations occurring in these chemically induced mouse
skin tumors have also been observed in the homologous
cutaneous tumors in humans (Balmain and Harris,
2000). ped/pea-15 might represent a novel target for
cutaneous cancer treatment and prevention.
Materials and methods
Transgenic ped/pea-15 mice
The C57BL/6JxDBA/2J ped/pea-15 transgenic mice were
described in Vigliotta et al. (2004). The animals were
maintained in the animal facility at the Dipartimento di
Biologia e Patologia Cellulare e Molecolare, Federico II
University of Naples. Experiments involving animals were
conducted in accordance with accepted standards of animal
care and the Italian regulations for the welfare of animals. The
study protocol was approved by the Institutional Committee
on Animal Care of the University of Naples.
Two-stage skin carcinogenesis
The dorsal skin of 8-week-old mice were shaved, and, 2 days
later, a single dose of 50mg of 7,12-dimethylbenz[a]anthracene
(DMBA) in 200ml of acetone was applied. At 1 week after
initiation, the mice were treated with 6.25mg of 12-O-
tetradecanoylphorbol-13-acetate (TPA) in 200ml of acetone
ped/pea-15 transgenic mice and skin cancer
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twice a week for 15 weeks. The number of papillomas detected
by palpation was recorded once a week.
At 1 week after termination of TPA treatment, mice were
killed, and skin tissues snap frozen in liquid nitrogen and/or
ﬁxed in freshly prepared 4% paraformaldehyde followed by
parafﬁn embedding. Mice were maintained for 35 additional
weeks after TPA discontinuation, and tumor progression was
investigated. Tumors were scored as papillomas or carcinomas
by histological analysis after H&E staining of parafﬁn
sections.
Histology
Tissues were ﬁxed in formalin, dehydrated, blocked in parafﬁn
and sectioned at 6mm. The tissue sections were stained with
hematoxylin and eosin. A total of 76 nonmalignant papillomas
and all malignant tumors were examined. Malignant skin
tumors were densely cellular spindle cell tumors in the dermis
underlying the papilloma, often exhibiting invasion through
skeletal muscle and sometimes associated with lymph node
metastasis. Premalignant lesions were squamous cells showing
atypia (enlarged nuclei, mitotic activity) but not associated
with spindle cell proliferation, invasion and metastasis.
Cell culture and growth, transfection and Western blot analysis
The C5N, P1 and A5 cells have been previously described
(Portella et al., 1998) and were kindly provided by Dr A
Balmain (University of California, San Francisco, Compre-
hensive Cancer Center, USA). Cells were cultured in DMEM
supplemented with 10% foetal calf serum, 10 000U/ml
penicillin, 10 000mg/ml streptomycin and 2% L-glutamine in
a humidiﬁed CO2 incubator as described in Portella et al.
(1998). Transfection of the constitutively active H-Ras61 in
C5N cells, tissue collection and Western blots were performed
as described in Vigliotta et al. (2004). The pcDNA-ped/pea-15
antisense construct has been previously described (Hao et al.,
2001). Clones expressing the antisense were selected as in Hao
et al. (2001). Soft agar colony assays were performed accord-
ing to a previously described technique (Macpherson and
Montagnier, 1964). The antibodies used include ped/pea-15
antibodies (Vigliotta et al., 2004), phosphoserine104ped/pea-15
and phosphoserine116ped/pea-15 antibodies (Trencia et al.,
2004), tubulin, caspase-3, XIAP and PARP antibodies (Santa
Cruz Biotechnology, CA, USA).
Detection of apoptosis
Animals were subjected to topical applications of acetone-
dissolved TPA (6.25 mg) or DMBA (50 mg) or acetone alone, as
indicated. The animals were killed, skin tissues were removed
and then solubilized as in Vigliotta et al. (2004) and processed
for the apoptosis assay using the Cell Death Detection
ELISAPLUS Kit (Roche Diagnostics GmbH, Mannheim,
Germany), according to the manufacturer instructions. For
studies in isolated cells, apoptosis was investigated as
previously described (Trencia et al., 2004).
Tumorigenicity assay
Experiments were performed in 6-week old male athymic mice
(Charles River, Italy). A5 cells (1 106), either transfected with
the ped/pea-15 antisense cDNA or not, were injected into
the right ﬂank of the mice. The animals were monitored for
the appearance of tumors and tumor latency was evaluated.
The mean tumor latency is the time needed for tumors to reach
10mm in diameter. All mice were maintained at the animal
facility of the Dipartimento di Biologia e Patologia Cellulare e
Molecolare of the Federico II University of Naples.
Densitometry and statistical analysis
Densitometric analysis was performed using a Scion Image
Analyser. All the data were expressed as mean7s.d.
Signiﬁcance was assessed by Student’s t-test for comparison
between two means.
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Abstract
Aims/hypothesis Overexpression of the gene encoding
phosphoprotein enriched in astrocytes 15 (PEA15), also
known as phosphoprotein enriched in diabetes (PED),
causes insulin resistance and diabetes in transgenic mice
and has been observed in type 2 diabetic individuals. The
aim of this study was to investigate whether PEA15
overexpression occurs in individuals at high risk of diabetes
and whether it is associated with specific type 2 diabetes
subphenotypes.
Subjects and methods We analysed PEA15 expression in
euglycaemic first-degree relatives (FDR) of type 2 diabetic
subjects.
Results The expression of PEA15 in peripheral blood
leucocytes (PBLs) paralleled that in fat and skeletal muscle
tissues. In PBLs from the FDR, PEA15 expression was
two-fold higher than in euglycaemic individuals with no
family history of diabetes (control subjects), both at the
protein and the mRNA level (p<0.001). The expression of
PEA15 was comparable in FDR and type 2 diabetic
subjects and in each group close to one-third of the subjects
expressed PEA15 levels more than 2 SD higher than the
mean of control subjects. Subjects with IFG with at least
one type 2 diabetes-affected FDR also overexpressed
PEA15 (p<0.05). In all the groups analysed, PEA15
expression was independent of sex and unrelated to age,
BMI, waist circumference, systolic and diastolic BP, and
fasting cholesterol, triacylglycerol and glucose levels.
However, in euglycaemic FDR of type 2 diabetic subjects,
PEA15 expression was inversely correlated with insulin
sensitivity (r=−557, p=0.01).
Conclusions/interpretation We conclude that PEA15 over-
expression represents a common defect in FDR of patients
with type 2 diabetes and is correlated with reduced insulin
sensitivity in these individuals.
Keywords Insulin resistance . PED .PEA15 .
Type 2 diabetes
Abbreviations
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Introduction
Phosphoprotein enriched in astrocytes 15 (PEA15), also
known as phosphoprotein enriched in diabetes (PED) is a
small scaffold protein widely produced in different tissues
and highly conserved among mammals [1–3], whose gene
(PEA15) maps on human chromosome 1q21–22 [4].
Several studies in cultured cells and in rodent tissues have
revealed that Pea15 regulates multiple cellular functions by
binding components of major intracellular transduction
pathways. PEA15 activates extracellular-regulated kinase
(ERK) 1/2 [3, 5]. It binds ERKs in the nucleus, exporting
them into the cytoplasm, thus preventing cell cycle entry
caused by sustained phospho-ERK nuclear accumulation
[5, 6]. PEA15 also interacts with protein kinase B (Akt/
PKB) and p90 ribosomal S6 kinase isozyme (RSK2), two
key components of the phosphoinositide 3-kinase (PI3-K)
and ERK signalling pathways, whose activation is central
to control of cell survival [7, 8]. In addition, PEA15 exerts
a wide anti-apoptotic action. It binds Fas-associated death
domain (FADD) and caspase-8, thereby protecting against
cytokine-induced apoptosis [9–11]. PEA15 also binds to
Omi/HtrA2 to inhibit apoptosis triggered by stress and
physical agents [12]. Importantly, there is evidence indicat-
ing that PEA15 anti-apoptotic action has an important role
in the development and progression of certain cancers in
humans as well as in rodents [13–15].
Recent reports further revealed that PEA15 binds to and
enhances phospholipase D stability, resulting in increased
intracellular levels of diacylglycerol [16, 17]. This effect
deregulates protein kinase C (PKC) signalling and gener-
ates resistance to insulin action on glucose transport in
muscle and adipose cells and in tissues from transgenic
mice overexpressing the Pea15 gene [17, 18]. Inhibited
glucose-regulated insulin secretion has also been reported
in these animals, contributing to their impaired glucose
tolerance. The Pea15 transgenic mice develop diabetes
upon weight gain, indicating an important interaction
between obesity and the Pea15 gene [18].
Earlier findings in humans evidenced that the PEA15
gene is overexpressed in skeletal muscle and fat tissues as
well as in cultured skin fibroblasts from individuals with
type 2 diabetes, and this effect occurs independently of
obesity, suggesting that it may be a primary component of
insulin resistance in these subjects [4]. Whether PEA15
overexpression is also detectable in more easily accessible
cells, such as peripheral blood leucocytes, and whether it
represents a common abnormality in type 2 diabetes is
unknown. Whether the overexpression occurs in individuals
at high risk of diabetes, whether it associates with diabetes
risk factors other than obesity, and whether it relates to
specific type 2 diabetes phenotypes also remains to be
determined. The aim of the present work was to investigate
these issues in first-degree relatives of type 2 diabetic
individuals.
Subjects and methods
Subjects The subjects investigated in the present study
were recruited consecutively at the outpatient facilities of
the Department of Preventive Medical Sciences (DSMP),
the Metabolic Unit (DMCS) at the University of Naples
Federico II Medical School and the Metabolic Unit at the
University of Catanzaro ‘Magna Graecia’ (offspring from
the European Network on Functional Genomics of Type 2
Diabetes [EUGENE2] study). Written informed consent
was obtained from all participants. The study protocol was
approved by the ethics committees of the participating
institutions and conducted in accordance to the principles
of the Declaration of Helsinki as revised in 2000. The
euglycaemic individuals (n=150) were healthy employees
of the Campania Region who were not receiving pharma-
cological treatment, and were undergoing a routine health
survey at the DSMP. The presence of type 2 diabetes-
affected first-degree relatives (FDR) was ascertained
through a written questionnaire and further verified through
the medical history. The average number of relatives with
type 2 diabetes in the subgroup of FDR was 1.1. The type 2
diabetic patients (n=142) were recruited at the DMCS. Of
these individuals, 19% were treated with diet alone, 48%
with sulfonylureas and/or metformin, 30% with insulin
alone, and 3% with insulin and oral hypoglycaemic agents.
The mean diabetes duration was 11±9 years. The mean
HbA1c level of the diabetic patients was 7.0±1.0%. Of the
diabetic patients, 48% showed no evidence of long-term
complications; 24% had microvascular and 12% had
macrovascular complications; 16% had both microvascular
and macrovascular complications. Anthropometric indexes
(BMI was calculated by dividing the weight in kilograms
by the square of the height in metres; waist circumference
was measured midway between the lowest rib margin and
the iliac crest to the nearest 0.5 cm) and detailed medical
history (including information on type 2 diabetes-affected
relatives and smoking habit) were obtained from all of the
participants through identical procedures at each participat-
ing institution. Blood pressure values were measured in the
left arm of the supine patient, after 5 min of quiet rest, with
a mercury sphygmomanometer. For each subject, whole-
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blood samples were drawn from an antecubital vein in the
morning after an overnight fast on two separate occasions.
Plasma glucose, total cholesterol, HDL cholesterol, triacyl-
glycerol and serum insulin levels were determined in a
centralised facility as described previously [19, 20].
Diagnoses of type 2 diabetes and IFG were established
according to criteria listed previously [21]. For studies in
matchedgroups (n=115) further individuals were recruited at
the DSMP. Inclusion criteria in this arm of the study were as
follows: age 52–58 years, BMI 26–32 kg/m2, waist
circumference 90–100 cm, systolic BP 120–140 mmHg,
diastolic BP 70–85 mmHg, total cholesterol 4.9–5.4 mmol/l,
HDL cholesterol 1.2–1.4 mmol/l, serum triacylglycerol 1.4–
1.6 mmol/l. Fifty-six type 2 diabetic individuals (mean
disease duration 11±4 years, mean HbA1c level 7.2±4.0%)
and 59 healthy euglycaemic subjects (of which 34 had no
family history of type 2 diabetes and 25 had at least one
type 2 diabetes-affected FDR) were consecutively enrolled.
Studies in euglycaemic offspring of type 2 diabetic patients
were performed using the EUGENE2 cohort http://www.
eugene2.com, last accessed in August 2006; [20, 22, 23] at
the University of Catanzaro Magna Graecia. The clinical
characterisation of these individuals has been previously
reported [20, 22, 23]. The OGTT and euglycaemic–hyper-
insulinaemic clamp procedures have also been previously
reported [20]. Briefly, for clamp studies, insulin (Humulin;
Eli Lilly, Indianapolis, IN, USA) was given as a prime
continuous infusion to produce plasma insulin levels of
∼420 pmol/l. Thereafter, the insulin infusion rate was fixed
at 40 mU m−2 min−1. Blood glucose was maintained at a
constant level throughout the study by infusing 20% glucose
at varying rates according to blood glucose measurements
performed at 5-min intervals. Lean body mass was assessed
by bioimpedence. Duration of the clamp was 120 min.
Glucose disposal is expressed as milligrams per kilogram of
lean body per mass per minute. Insulin secretion was
estimated by the homeostasis model assessment of pancre-
atic beta cell function (HOMA-B) index [24] and the
insulinogenic index as the difference between the 30- and
0-min OGTT plasma insulin values divided by the differ-
ence between the corresponding plasma glucose values,
(ΔI30/ΔG30), as described previously [25].
Separation of white blood cells and tissue sampling For
peripheral blood leucocyte (PBL) separation, EDTA-treated
whole-blood samples were first centrifuged at 300 ×g for
10 min and the plasma removed. PBLs were separated
using a 6% dextran gradient in filtered PBS, pH 7.4, as
previously described [26], washed in PBS three times,
counted and resuspended in 1 ml of PBS for subsequent
use. Neutrophils and other major leucocyte subpopulations
were further separated as previously described [26, 27]. The
purity of the different cell populations was confirmed by
microscopic examination. Subcutaneous adipose tissue
from the anterior abdominal wall and skeletal muscle
(rectus abdominis) biopsies were obtained simultaneously
from patients undergoing elective abdominal surgery for
gall bladder disease. For this part of the study, the diabetic
patients and the euglycaemic subjects (with and without
type 2 diabetic FDR in their pedigree) were consecutively
recruited to achieve a 1:1:1 ratio between the three groups
(total n=21). Tissues were rinsed and dissected free of
erythrocytes and connective tissues, as previously described
[28]. PBLs were collected at the same time as fat and
muscle specimens.
Cell and tissue harvesting and western blotting PBL
and tissue samples were solubilised at 4°C in TAT
buffer (50 mmol/l HEPES, pH 7.5, 150 mmol/l NaCl,
10 mmol/l EDTA, 10 mmol/l Na4P2O7, 2 mmol/l Na3VO4,
100 mmol/l NaF, 10% glycerol, 1% Triton X-100) supple-
mented with 1 mmol/l phenylmethanesulfonylfluoride and
10 μg/ml aprotinin, as described previously [28]. Lysates
were centrifuged at 500 ×g for 20 min and supernatant
fractions were frozen at −20°C until used. For Western
blotting, 50 μg of lysate proteins were heated at 100°C in
Laemmli buffer [29]. Proteins were separated by 15% SDS-
PAGE and then transferred to 0.45-mm Immobilon-P
membranes (Millipore, Bedford, MA, USA). Filters were
probed with phospholipase D1 (PLD1) (BioSource Interna-
tional, Camarillo, CA, USA) or PEA15 antibodies [4],
revealed by enhanced chemiluminescence and autoradiogra-
phy, and PEA15 bands were quantitated by laser densitom-
etry. Inter-assay variation was <15%.
RNA samples and real-time RT-PCR RNA from white
blood cells were immediately extracted following cell
isolation using the QIAamp RNA Blood Mini Kit (Qiagen,
Valencia, CA, USA) according to the manufacturer’s
instructions. PEA15 gene expression was measured by
real-time RT-PCR (SYBRGreen with iCycler IQ Multicolor
Real-Time Detection System, Biorad, Richmond, VA,
USA). The following primer pairs were designed using
the Beacon Designer Software (Biorad) based on published
gene sequences (GeneBank Accession nos. AH008227
and M10277, respectively). Human hped1 (forward)
5′-GAGCGCTCAGCTCCAGAGG-3′; human hped3 (re-
verse) 5 ′-CAGGACGGCGGGAGATCT-3 ′; human
β-actin (forward) 5′-TGCGTGACATTAAGGAGAAG-3′;
human β-actin (reverse) 5′-GCTCGTAGCTCTTCTCCA-3′.
Real-time RT-PCR was performed with a cDNA input of
50 ng total RNA with all combinations of primers. Data
acquisition and analysis were automatically performed by
the iCycler IQ Multicolour Real-Time Detection System
Optical System Software, version 3.1 (Biorad). Primers for
real-time detection of PLD1 were as follows. Human PLD1
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(forward) 5′-TGGGACCAAAGGGCATAGAAGG-3′ human
PLD1 (reverse) 5′-TACCAGCAGGACGAAGG CAATG-3′.
Statistical analysis Data are means±SEM. Comparisons
between groups were tested by the unpaired Student’s t test
or the Mann–Whitney U test, and among groups by
ANOVA. Mean values, after adjusting for covariates, were
evaluated by ANCOVA. A p value of < 0.05 was
considered significant. Analyses were performed using the
statistical package SPSS, version 12 (SPSS, Chicago, IL,
USA).
Results
To identify tissues for which PEA15 expression can be non-
invasively quantified in a large number of subjects, we first
analysed lysates from PBLs by immunoblotting with
specific PEA15 antibodies [4]. In samples from 21 subjects
(seven with type 2 diabetes, seven euglycaemic subjects
with diabetic FDR [EuF+], and seven euglycaemic
subjects with no family history of diabetes [EuF−]), these
assays revealed the expression of PEA15, with no signif-
icant differences between the granulocyte, lymphocyte and
monocyte cells (Fig. 1a). On a per-mg-protein basis, PEA15
levels in these cells were 30% higher than those in human
skeletal muscle and adipose tissues (p<0.001). Importantly,
in these same subjects, there were significant correlations
between PEA15 levels in the PBLs and those in fat and in
skeletal muscle tissues (p<0.001; Fig. 1a,b).
We then compared the levels of PEA15 in PBL lysates
from 30 EuF+ individuals (these subjects are known to be
at increased risk of diabetes [30, 31]) with those in PBL
lysates from 120 EuF− subjects. Their clinical character-
istics are shown in Table 1. A two-fold increase in PEA15
levels was found in the EuF+ subjects (p<0.001; Fig. 2a).
This increase was of a similar magnitude to that observed in
an additional group of 142 type 2 diabetic patients, whose
clinical features are also shown in Table 1. As in the case of
the type 2 diabetic patients, close to one-third of the EuF+
subjects expressed amounts of PEA15 protein that were
more than two SDs higher than the mean for the EuF−
subjects. As previously demonstrated in isolated fibroblasts,
skeletal muscle and adipose tissues from type 2 diabetic
individuals [4], the increased levels of PEA15 protein
detected in PBLs from the EuF+ and the type 2 diabetic
subjects occurred in parallel with an increase in PEA15
mRNA (Fig. 2b). Also, the increased PEA15 gene
expression in the EuF+ and the type 2 diabetic individuals
was paralleled by a three-fold increase in levels of the
PEA15 downstream target PLD1 (p=0.001; Fig. 2c), with
no change in PLD1 mRNA (data not shown).
As in our previous report [4], in the present study we
found no difference in PEA15 expression between the
obese and lean individuals, irrespective of whether they
were euglycaemic or diabetic (data not shown). To address
Fig. 1 Expression of PEA15 protein in human white blood cells.
a PBLs and the relative granulocyte, lymphocyte and monocyte
fractions were prepared from samples from 21 individuals (type 2
diabetic, EuF+ and Eu− subjects at a 1:1:1 ratio). Biopsy specimens of
skeletal muscle and adipose tissues from these same patients were
collected at the time they underwent elective abdominal surgery, as
described in the Subjects and methods section. Cells and tissues were
solubilised and analysed by western blotting PEA15 antibodies [4].
Blots were revealed by enhanced chemiluminescence and autoradiog-
raphy, and PEA15 levels quantified by laser densitometry. Bars
represent the means ± SEM of four independent experiments.
Asterisks indicate statistical significance between bracketed columns
(p<0.001). Correlation between PEA15 levels in PBLs and muscle
(r=0.881, p<0.001) (b) or fat (r=0.845, p<0.001) (c) was tested by
linear regression analysis, as described in Subjects and methods
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the effect of other major risk factors for type 2 diabetes, we
analysed the levels of PEA15 in 55 further individuals
diagnosed with IFG according to a previous report [21].
Ten of these subjects had at least one type 2 diabetes-
affected FDR (IFG-F+), while the others had no family
history of disease (IFG-F−). PBL levels of PEA15 in IFG-
F− subjects were found to be very comparable to those
detected in EuF− subjects (Fig. 3a). As in the case of the
euglycaemic individuals, however, IFG-F+ subjects
exhibited PEA15 levels that were significantly greater than
those detected in the IFG-F− subjects (p<0.05), further
pointing to an important effect of family history on PEA15
levels in euglycaemic and IFG humans.
In the euglycaemic subjects (both EuF+ and EuF−) and
in the type 2 diabetic patients described in Table 1, there
were no sex-related differences in PEA15 level. Also, no
significant correlation was found between the production of
PED15 and the age, BMI, waist circumference, systolic BP
or diastolic BP, fasting cholesterol, triacylglycerol or
glucose levels of the subjects (data not shown), indicating
that PEA15 levels are independent of these variables in
humans. To further examine this hypothesis, we compared
PEA15 levels in three additional groups of consecutively
recruited euglycaemic (EuF+ and EuF−) and type 2 diabetic
individuals matched for age, BMI, waist circumference,
systolic BP and diastolic BP, and fasting HDL cholesterol
Table 1 Clinical and biochemical features of the euglycaemic and
type 2 diabetic individuals
Parameter EuF−
subjects
(n=120)
EuF+
subjects
(n=30)
Type 2
diabetic
subjects
(n=142)
Sex (male/female) 84/36 14/16 90/52
Age (years) 49±9 49±6 58±10*
Smokers (%) 27 20 21
BMI (kg/m2) 28±5 28±3 29±4
Systolic BP (mmHg) 126±15 128±16 134±21**
Diastolic BP (mmHg) 79±9 81±9 80±9
Total serum cholesterol (mmol/l) 6.1±1.2 5.8±1 5.2±0.9**
HDL cholesterol (mmol/l) 1.4±0.4 1.4±0.3 1.2±0.4**
Serum triacylglycerol (mmol/l) 1.5±0.7 1.3±0.5 1.9±1.6**
Fasting plasma glucose (mmol/l) 5.0±0.4 5.0±0.3 9.4±3**
Fasting plasma insulin (μU/ml) 4±3 9±3* –
Data are presented as the means±SEM or %
*p<0.01 vs EuF− subjects
**p<0.001 vs EuF− subjects
Fig. 2 Expression of PEA15 in PBLs from euglycaemic subjects.
a PBLs from 30 euglycaemic individuals with at least one type 2
diabetic FDR (EuF+) and 120 euglycaemic subjects lacking a family
history of diabetes (EuF−) were consecutively collected. For compar-
ison, PBLs from 142 type 2 diabetic patients (T2D) were also analysed.
Cells were solubilised and PEA15 (a) and PLD protein levels (c) were
quantified in the lysates as outlined in the legend to Fig. 1. Data points
represent the mean of three independent determinations in each
individual subject. RNA was extracted from PBLs and PEA15 mRNA
(b) quantified by real-time PCR as described in the Subjects and
methods section. Data points are the means of three independent
determinations in each individual subject

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and triacylglycerol levels (Table 2). A two-fold increase in
PEA15 levels was again observed in both the diabetic
subjects and the EuF+ subjects compared with the EuF−
subjects (p<0.01; Fig. 3b), providing corroborating evidence
that PEA15 is independent these variables in humans.
To address the functional significance of PEA15 over-
expression in type 2 diabetic FDR, we searched for
associations with diabetes-related phenotypes. We analysed
an additional group of 25 euglycaemic offspring of type 2
diabetes-affected couples from the EUGENE2 cohort http://
www.eugene2.com, last accessed in August 2006; [20, 22,
23]. PBL expression levels of PEA15 in these offspring
were comparable to those of the other type 2 diabetic FDR
investigated in this study (Table 3). The other clinical
characteristics of these subjects are also shown in Table 3.
A negative correlation was evidenced between the individ-
ual levels of PEA15 in PBLs and insulin-stimulated glucose
disposal according to fat-free mass, as determined by the
euglycaemic–hyperinsulinaemic clamp (r=−557, p=0.01;
Fig. 3c). Insulin-stimulated glucose disposal also negatively
correlated with BMI in these individuals (r=−0.64, p=0.01).
However, the correlation with PEA15 levels remained
significant after adjustment for age, sex and BMI (r=−491,
p=0.02). As in the case of the other FDR investigated in this
study, PEA15 levels did not correlate with age, BMI, waist
circumference, SBP or DBP, or fasting cholesterol, triacyl-
glycerol or glucose levels in these offspring (data not
shown). Thus, the overexpression of PEA15 may induce
insulin-resistance in euglycaemic offspring of type 2
diabetes-affected couples.
Discussion
Previous studies have reported that PEA15 is a multifunc-
tional protein that controls a number of cellular functions,
including proliferation, apoptosis and insulin-regulated
glucose transport [4–12, 17, 18, 32]. In transgenic mice
fed high-fat diets, the overexpression of Pea15 leads to
diabetes [18]. In humans, no genetic variability accounting
for the differential expression of the PEA15 gene has been
identified to date. However, PEA15 overexpression was
shown to occur in skeletal muscle and adipose tissues from
type 2 diabetic patients, independently of drug treatment
and obesity [4]. Whether this abnormality is associated with
other risk factors for type 2 diabetes is unknown, as is
whether it contributes to specific phenotype(s) associated
with diabetes in humans. In the present work we have
addressed these questions in FDR of type 2 diabetic
subjects. These individuals have a very high risk of type
2 diabetes [30, 31] and develop different diabetes-related
phenotypes years before diabetes onset, independently of
the metabolic abnormalities associated with this disorder
[33–35]. We have shown that the PEA15 gene is overex-
pressed in PBLs from EuF+ subjects. As previously shown
Fig. 3 Type 2 diabetes-associated phenotypes and risk-factors related
to PEA15 expression. a PBL were obtained from 55 consecutive
individuals with IFG diagnosed as described previously [21]. Ten of
these subjects had at least one type 2 diabetes-affected FDR (IFG-F+),
while the others had no family history of diabetes (n=45; IFG-F−).
Cells were solubilised and PEA15 protein levels were quantified in the
lysates as outlined in the legend to Fig. 1. For comparison, data
obtained from PBL from the euglycaemic subjects lacking a family
history of diabetes and shown in Fig. 2 (EuF−) are also presented. b Two
further groups of euglycaemic subjects with (n=25; EuF+) or without
(n=36; EuF−) a family history of type 2 diabetes and of type 2
diabetic subjects (n=58; T2D) were matched for age, BMI, waist
circumference, systolic BP and diastolic BP and fasting cholesterol
and triacylglycerol levels as described in the Subjects and methods
section. PBLs from these subjects were obtained and solubilised, and
PEA15 protein levels quantitated in the lysates as outlined in the
legend to Fig. 1. Bars represent the mean ± SEM of three (a) or four
(b) independent experiments, each in duplicate. Asterisks indicate
statistical significance between bracketed columns (p<0.001). c PEA15
protein levels were determined in PBLs from 25 euglycaemic offspring of
couples, one of which was affected by type 2 diabetes. Glucose disposal
was assessed by the euglycaemic–hyperinsulinaemic clamp as described
in the Subjects and methods section and corrected for fat-free mass.
Linear regression analysis performed as described in the Subjects and
methods section revealed a correlation between PEA15 levels in PBLs
and glucose disposal (r=−0.557, p=0.01)
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in cells from type 2 diabetic subjects [4], this over-
expression occurs at both the mRNA and protein level
indicating that, as previously demonstrated in cells from
type 2 diabetic subjects [4], it is caused, at least in part, by a
transcriptional abnormality. Earlier studies in isolated cells
and in vivo showed that PEA15 binds to and increases the
cellular stability of PLD1, deregulating PKC signalling and
impairing insulin-dependent glucose disposal [17, 18]. We
now show that enhanced PLD1 stability also appears to occur
in PBLs from type 2 diabetic subjects and FDR, suggesting
that it occurs in individuals who overexpress PEA15. Indeed,
in parallel with PEA15, cells from both type 2 diabetic and
EuF+ individuals exhibit PLD protein levels that are three
times higher than those seen in EuF− individuals, with no
change in mRNA. PEA15 levels in the PBLs are closely
correlated with those in fat and skeletal muscle tissues. Thus,
although PBLs do not represent a classical target for insulin,
they do allow the non-invasive investigation of the role of
PEA15 overexpression during progression towards type 2
diabetes. In this study the overexpression of PEA15 relative
to the expression seen in EuF− individuals was demonstrated
in almost one-third of the EuF+ subjects and in a similar
proportion of the type 2 diabetic subjects. It appears therefore
that increased PEA15 levels represent a common abnormality
in both type 2 diabetic subjects and individuals at increased
risk of this disease, suggesting that it might precede diabetes
onset in the latter.
In both type 2 diabetic subjects and their FDR, PEA15
levels were independent of BMI, waist circumference,
systolic and diastolic blood pressure, HDL cholesterol,
triacylglycerol and glucose levels, indicating that expression
of the PEA15 gene is independent of the main variables
associated with the metabolic syndrome in humans. PEA15
levels were also not related to sex or age, or to reduced
physical activity or smoke habit, two recognised risk factors
for type 2 diabetes and insulin resistance. Interestingly, we
report that, similar to EuF+ individuals, individuals with IFG
who are FDR of type 2 diabetic individuals (IFG-F+) also
exhibit high levels of PEA15. In contrast, IFG subjects
lacking a family history of type 2 diabetes (IFG-F−) do not,
further indicating familiar clustering of this trait. The
overexpression of the PEA15 gene in the type 2 diabetic
subjects and their FDR may be genetically or environmen-
tally determined, or determined by both factors. Indeed,
previous studies [4] have shown that the overexpression
persists in human skin fibroblasts after several generations in
culture, suggesting that the occurrence of similarly high
PEA15 levels in the EuF+, IFG+ and type 2 diabetic
individuals is at least partly a genetically determined effect.
At variance with these euglycaemic and IFG individuals, the
presence of a FDR affected by type 2 diabetes had no effect
on PEA15 levels in patients with an established diagnosis of
type 2 diabetes (data not shown). Once deranged glucose
tolerance enables overt diabetes to occur, factors secondary
to the disease might modify PEA15 gene expression and/or
PEA15 protein levels, thereby masking the primary over-
expression. Consistent with this possibility, recent studies by
Table 3 Clinical and biochemical features of the type 2 diabetic
offspring
Parameter Mean ± SEM
Number (male/female) 13/12
Age (years) 30.1±8.3
BMI (kg/m2) 24.5±4.1
Waist circumference (cm) 83.5±12.2
Systolic BP (mmHg) 112±11
Diastolic BP (mmHg) 75±6
Total cholesterol (mmol/l) 4.8±0.9
HDL cholesterol (mmol/l) 1.5±0.3
Triacylglycerol (mmol/l) 1±0.7
Fasting plasma glucose (mmol/l) 4.8±0.5
2-h glucose (mmol/l) 5.8±1.4
Fasting plasma insulin (pmol/l) 55.6±20.8
Fat-free mass glucose disposal (mg kg LBM−1 min−1) 12±3
HOMA-IR 1.8±0.9
HOMA-B 174±65
Insulinogenic index (ΔI30/ΔG30) 18±12
PEA15 (arbitrary units) 257±35
Data are presented as the means ± SEM
HOMA-B Homeostasis model assessment of pancreatic beta cell
function, HOMA-IR homeostasis model assessment of insulin
resistance, LBM lean body mass
Table 2 Clinical and biochemical features of matched euglycaemic
and type 2 diabetic individuals
Parameter EuF−
subjects
(n=34)
EuF+
subjects
(n=25)
Type 2
diabetic
subjects
(n=56)
p value
Sex (male/female) 20/14 10/15 33/23 –
Age (years) 54±2 56±1 55±2 NS
Smokers (%) 25 23 24 NS
BMI (kg/m2) 29±3 28±2 29±2 NS
Waist circumference (cm) 93±6 94±3 95±3 NS
Systolic BP (mmHg) 132±6 128±7 130±8 NS
Diastolic BP (mmHg) 82±5 80±4 79±10 NS
Total serum cholesterol
(mmol/l)
5.2±0.3 5.2±0.2 5.3±0.1 NS
HDL cholesterol
(mmol/l)
1.2±0.1 1.2 ±0.1 1.2±0.1 NS
Serum triacylglycerol
(mmol/l)
1.4±0.1 1.4±0.1 1.5±0.1 NS
Fasting plasma glucose
(mmol/l)
5.0±0.3 5.1±0.3 9.5±3.1 <0.001
Data are presented as the means ± SEM or %. Statistical significance
was assessed by comparing all three groups of subjects
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our own as well as other laboratories have shown that PEA15
is highly regulated at the post-translational level [1, 2, 7, 12].
Previous studies in cultured cells and in transgenic mice
have shown that overexpression of the gene encoding
PEA15 determines resistance to insulin action and impairs
glucose-induced insulin secretion. In this study, we inves-
tigated whether PEA15 overexpression is associated with
impaired insulin action and/or secretion in euglycaemic
offspring of type 2 diabetes-affected couples. In these
individuals, who are at increased risk of diabetes, insulin
resistance and reduced non-oxidative glucose metabolism
appear years before the onset of hyperglycaemia [33, 34].
Using results from euglycaemic–hyperinsulinaemic clamp
studies, a negative correlation was established between
PEA15 levels and the insulin-stimulated glucose disposal
by the fat-free mass of the offspring, suggesting that high
levels of PEA15 protein contribute to development of
skeletal muscle resistance to insulin action in these
individuals. PEA15 levels were also weakly correlated with
fasting plasma insulin in these FDR, but not in euglycaemic
individuals lacking a family history of type 2 diabetes (data
not shown). PEA15 might induce insulin resistance only in
conjunction with other diabetes-related genes enriched in
at-risk individuals. In this case, as previously demonstrated
by Mootha et al. [36], gene enrichment analysis [37] may
help to further unravel the mechanistic significance of
increased levels of PEA15 in human diabetes. However,
whether the PEA15 effect is weaker in individuals lacking a
particular, as-yet-undefined, genetic background cannot be
concluded from these studies. Indeed, unlike the hyper-
glycaemic–euglycaemic clamp, fasting plasma insulin is a
very crude index of insulin sensitivity [38]. In addition to
insulin resistance, offspring of type 2 diabetes-affected
couples may also have beta cell dysfunction, as evidenced
by decreases in insulin and amylin secretion in response to
glucose stimulation [35]. However, PEA15 levels were not
correlated with any index of beta cell function in the
offspring. Overexpression of the gene may impair glucose-
triggered insulin secretion in transgenic mice but not in
humans. This is unlikely, however, as transfection of a
PEA15 cDNA in human beta cell lines grossly impairs the
insulin response to glucose (data not shown). Alternatively,
in the type 2 diabetic FDR, the consequence of the high
PEA15 levels on insulin action might occur earlier during
life than the PEA15 effect on beta cell function.
In conclusion, in the present study we have shown that
PEA15 overexpression represents a common abnormality in
both type 2 diabetic patients and their FDR and can be
conveniently detected in PBLs. In at-risk individuals, this
defect is associated with the presence of a type 2 diabetes-
affected FDR and not with other major type 2 diabetes risk
factors. In euglycaemic FDR of type 2 diabetic patients, high
PEA15 levels are strongly correlated with resistance to
insulin action in the lean mass, suggesting that PEA15
contributes to the early appearance of insulin resistance in
these individuals. Follow-up studies are in progress to further
elucidate the effect of PEA15 levels in type 2 diabetes.
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